<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id>
<journal-id journal-id-type="iso-abbrev">Oxid Med Cell Longev</journal-id>
<journal-id journal-id-type="publisher-id">OMCL</journal-id>
<journal-title-group>
<journal-title>Oxidative Medicine and Cellular Longevity</journal-title>
</journal-title-group>
<issn pub-type="ppub">1942-0900</issn>
<issn pub-type="epub">1942-0994</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32908622</article-id>
<article-id pub-id-type="pmc">7450359</article-id>
<article-id pub-id-type="doi">10.1155/2020/1370837</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Parkinson's Disease-Induced Zebrafish Models: Focussing on Oxidative Stress Implications and Sleep Processes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Robea</surname>
<given-names>Madalina-Andreea</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balmus</surname>
<given-names>Ioana-Miruna</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-1750-6011</contrib-id>
<name>
<surname>Ciobica</surname>
<given-names>Alin</given-names>
</name>
<email>alin.ciobica@uaic.ro</email>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Strungaru</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Plavan</surname>
<given-names>Gabriel</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-6454-9092</contrib-id>
<name>
<surname>Gorgan</surname>
<given-names>Lucian Dragos</given-names>
</name>
<email>lucian.gorgan@uaic.ro</email>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Savuca</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nicoara</surname>
<given-names>Mircea</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Department of Biology, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, Carol I Avenue, No. 20A, Iasi, Romania</aff>
<aff id="I2">
<sup>2</sup>Department of Interdisciplinary Research in Science, “Alexandru Ioan Cuza” University of Iasi, Carol I Avenue, No. 11, Iasi, Romania</aff>
<aff id="I3">
<sup>3</sup>Department of Research, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, Carol I Avenue, No. 20A, Iasi, Romania</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Daniel Lopez-Malo</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>2020</volume>
<elocation-id>1370837</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="rev-recd">
<day>7</day>
<month>7</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>7</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Madalina-Andreea Robea et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>The complex yet not fully understood pathophysiology of Parkinson's disease includes an important molecular component consisting of oxidative status changes, thus leading to oxidative stress occurrence. While no particular evidence has been reported that describes the relationship between oxidative stress and the molecular mechanisms behind Parkinson's disease development, animal model studies has shown that oxidative stress induction could modulate Parkinson's disease symptomatology. Despite the inability to perfectly replicate human disease in animals and despite that Parkinson's disease has not been reported in any animal species, animal modeling is one of the most important tools in understanding the complex mechanisms of human disorders. In this way, this study is aimed at detailing this particular relationship and describing the molecular mechanisms underlying Parkinson's disease in animal models, focusing on the potential advantages and disadvantages of zebrafish in this context. The information relevant to this topic was gathered using major scientific database research (PubMed, Google Scholar, Web of Science, and Scopus) based on related keywords and inclusion criteria. Thus, it was observed that oxidative stress possesses an important role in Parkinson's disease as shown by numerous animal model studies, many of which are based on rodent experimental models. However, an emerging impact of the zebrafish model was observed in the research of Parkinson's disease pathological mechanisms with regard to disease development factors and the cause-effect relationship between oxidative stress and comorbidities (such as depression, hyposmia, fatigue, sleep disturbances, and cognitive deficits) and also with regard to the pharmacological potential of antioxidant molecules in Parkinson's disease treatment.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>Operational Programme Human Capital 2014-2020</funding-source>
</award-group>
<award-group>
<funding-source>European Social Fund</funding-source>
<award-id>POCU/380/6/13/123623</award-id>
</award-group>
<award-group>
<funding-source>Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii</funding-source>
<award-id>PN-III-P1-1.1-TE-2016-1210</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Introduction</title>
<p>Oxidative stress (OS) greatly impacts the human body leading to well-known pathologies, such as diabetes, atherosclerosis, Alzheimer's disease, and Parkinson's disease (PD) [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. The main cause of OS occurrence is due to the imbalance between reactive oxygen species (ROS) production and the ability of the biological systems to transform ROS into harmless oxygen species (such as water), or to detoxify the intermediate metabolites or to repair the oxidative damage [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B3">3</xref>].</p>
<p>The concept of OS implication in mental illness was previously described [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]; however, it is controversial. It is generally known that, with several exceptions, the occurrence of mental illnesses consists of the interaction between genetic or developmental events and environmental factors [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Based on the context that mitochondrial dysfunction is facilitated by several different mechanisms and also on the fact that high levels of ROS are needed in the nervous system due to autophagy and mitophagy functions [<xref ref-type="bibr" rid="B8">8</xref>], OS occurrence in both the normal and pathological brain functions is currently accepted as a normal yet controlled mechanism.</p>
<p>Considering all these aspects, PD can be defined as a complex neuropsychiatric disorder occurring mostly in elders, which is commonly characterized by dopaminergic system malfunction leading to muscular tonus loss [<xref ref-type="bibr" rid="B9">9</xref>]. The exact cause of PD is unknown, but several hypotheses point at genetic inheritance, drugs, and environmental factors, such as pesticides, heavy metals, cigarette smoking, and caffeine [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>]. The administration of several chemical compounds can influence the entire cell metabolism leading to a cascade of events as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p>
<p>The emerging use of the zebrafish model in neurological and neurodegenerative human diseases (such as PD, autism, Huntington's disease, and Alzheimer's disease) was described by Xi et al. [<xref ref-type="bibr" rid="B12">12</xref>] and Brennan [<xref ref-type="bibr" rid="B13">13</xref>]. Despite that some disease phenotypes which are caused by orthologue genes can be very different, particularly when comparing fish and humans [<xref ref-type="bibr" rid="B14">14</xref>], it was shown that more than 70% of all human disease genes have functional homologs in <italic>Danio rerio</italic> [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. In this way, the fast growing and easy-to-breed zebrafish could be a reasonable choice when contemplating to keep thousands of animals at low costs [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. While zebrafish was originally considered as a bridge connection in the experimental gap between fly/worm and mouse/human in studying embryo development, it was shown that as the new research methodologies and genetic tools were updated, the zebrafish animal model was reported to be well suited to both developmental and genetic analysis [<xref ref-type="bibr" rid="B18">18</xref>] as well as complex human disorders [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>].</p>
<p>In this context, experimental animal models are needed to provide additional evidence on PD etiology, mechanisms, and possible therapeutic interventions. Thus, in this study, we aimed to describe the influence of OS on the Parkinsonian nervous system, as previously shown also by our research group on rodent models [<xref ref-type="bibr" rid="B12">12</xref>–<xref ref-type="bibr" rid="B15">15</xref>]. Furthermore, considering the emerging use of zebrafish in the novel worldwide research endeavours, we aimed to compare and elaborate the zebrafish neurophysiology model in PD research with regard to disease development factors, cause-effect relationship of OS and comorbidities (focussing on sleep disturbances), and the pharmacological potential of antioxidant molecules.</p>
</sec>
<sec id="sec2">
<title>2. Materials and Methods</title>
<p>The search strategy included the use of major scientific databases (PubMed, Google Scholar, Web of Science, and Scopus) for research of scientific articles published between 1990 and 2020. The following search keywords were used: “oxidative stress,” “Parkinson's disease,” “animal model,” “rat,” “mice,” “zebrafish,” “1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” “rotenone,” “paraquat,” and “neurotoxin.” The process of scientific article selection considered only reports written in English language, and the selection was conducted by four separate researchers (Robea M.-A., Balmus I.-M., Savuca A., and Ciobica A.) whose differences in opinion were resolved by common consent. After the initial scientific database research, all the scientific articles were reviewed considering some inclusion criteria, such as the reports that (1) included information/research data on the oxidative changes occurring in Parkinson's disease, or described the molecular pathways of Parkinson's disease in relation to human pathology, or presented significant results on Parkinson's disease treatments (in relation to oxidative balance pathways) and (2) included relevant information on the Parkinson's disease animal models (in relation to oxidative balance pathways), or described the molecular pathways of Parkinson's disease symptoms' means of modulation in animals, or presented significant results and correlations on the Parkinson's disease treatments (in relation to oxidative balance pathways and antioxidant potential). Exclusion criteria were formulated to avoid duplicate studies (i.e., studies on the same antioxidant molecule), studies not related to oxidative stress and Parkinson's disease pathological pathways, and irrelevant animal model studies in Parkinson's disease research (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
</sec>
<sec id="sec3">
<title>3. Parkinson's Disease and Oxidative Stress</title>
<p>PD is a progressive neurodegenerative disease, which predominantly occurs in the elderly population [<xref ref-type="bibr" rid="B24">24</xref>–<xref ref-type="bibr" rid="B26">26</xref>]. Characterized by loss of neurons from the substantia nigra, PD leads to inhibition of dopamine production and accumulation of Lewy bodies (LB) formed by <italic>α</italic>-synuclein aggregates, a presynaptic neuronal protein [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B27">27</xref>–<xref ref-type="bibr" rid="B29">29</xref>]. The result of these neuromolecular changes is translated into several clinical symptoms, such as bradykinesia, resting tremor, rigidity, and postural instability [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B31">31</xref>]. Several nonmotor symptoms, such as depression, hyposmia, fatigue, sleep disturbances, and cognitive deficits such as dementia are often considered comorbidities of PD [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B32">32</xref>].</p>
<p>Dopamine (DA) synthesis starts with tyrosine and two key enzymes (tyrosine hydrolase and amino acid decarboxylase), whereas its degradation is provided by the action of three key enzymes (monoamine oxidase B, catechol-O-methyl-transferase, and dopamine <italic>β</italic>-hydroxylase) resulting in two final metabolites and norepinephrine [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B33">33</xref>]. However, excess DA induces neuronal damage and cell death through ROS generation. Furthermore, ROS accumulation could lead to DNA mutations and to loss of dopaminergic neurons from the substantia nigra [<xref ref-type="bibr" rid="B33">33</xref>–<xref ref-type="bibr" rid="B35">35</xref>].</p>
<p>Considering that ROS can be produced by different biological structures, many ROS functions have been described mainly according to their reactivity. Mitochondria and metabolism are some of the most important sources of ROS, thus enzymes such as nitric oxide synthase, monoamine oxidase, and xanthine oxidase produce daily huge amounts of the following reactive oxygen and nitrosative species: superoxide (O<sub>2</sub><sup>∙–</sup>), hydroxyl (OH<sup>∙</sup>), peroxyl (ROO<sup>∙</sup>), nitric oxide (NO<sup>∙</sup>), nitrogen dioxide (NO<sub>2</sub><sup>∙</sup>), dinitrogen trioxide (N<sub>2</sub>O<sub>3</sub>), nitrosonium cation (NO+), nitroxyl anion (HNO), and lipid peroxyl (LOO<sup>∙</sup>) [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>].</p>
<p>Olanow and Tatton [<xref ref-type="bibr" rid="B34">34</xref>] and Asanuma et al. [<xref ref-type="bibr" rid="B38">38</xref>] both reported an increase in lipid peroxidation and a decrease in the activity of antioxidant enzymes, such as catalase (CAT), glutathione (GSH), and glutathione peroxidase (GPx), in PD patients. Furthermore, dysregulated metal ion homeostasis has been often reported in PD development, particularly iron [<xref ref-type="bibr" rid="B39">39</xref>]. High iron levels were discovered in the substantia nigra pars compacta which were presumed to lead to hydroxyl radical (OH) generation due to iron's redox instability [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>].</p>
<p>OS implication in PD is supported by postmortem studies and by numerous reports which suggested its active role in PD pathological processes [<xref ref-type="bibr" rid="B42">42</xref>]. A link between OS, mitochondrial dysfunction, and glutathione levels was suggested by Di Monte et al. [<xref ref-type="bibr" rid="B43">43</xref>] by the implications of DA metabolization by monoamine oxidase (MAO) during which the formation and accumulation of H<sub>2</sub>O<sub>2</sub> occurs. Simultaneously, the glutathione resources are depleted while glutathione peroxidase catalyses the reduction of H<sub>2</sub>O<sub>2</sub> in H<sub>2</sub>O [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>]. Furthermore, as a consequence of substantia nigra glutathione depletion and mitochondrial dysfunction, NO<sup>∙</sup> production increases and leads to <italic>α</italic>-synuclein (<italic>α</italic>-syn) accumulation [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B29">29</xref>].</p>
<p>In physiological conditions, oxidised glutathione (GSSG) is reduced by glutathione reductase in reduced glutathione (GSH) using NADPH. However, the GSH depletion could be caused by impaired synthesis of GSH, which is a result of mitochondrial dysfunction since there is not an adequate quantity of ATP to sustain the GSH production [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. To support this hypothesis, Hauser et al. [<xref ref-type="bibr" rid="B45">45</xref>] proved that GSH is reduced approximately 40-50% in PD patients.</p>
<p>Similarly, an important pathological mechanism underlying PD pathogenesis could be supported by nitric oxide action due to its capacity to impair synaptic activity, memory functionality, and neuronal plasticity [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. This aspect was suggested by Ravenstijn et al. [<xref ref-type="bibr" rid="B66">66</xref>] while showing that 7-nitroindazole could exhibit an inhibitory effect on nitric oxide synthase from the substantia nigra pars compacta leading to malonate, 3-nitropropionic acid, or MPTP-induced lesion attenuation [<xref ref-type="bibr" rid="B46">46</xref>].</p>
<p>As we previously described, mitochondrial dysfunction plays a major role in symptom persistence and disease progression [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. The decreased rate of ATP production leads to OS and further to cell death [<xref ref-type="bibr" rid="B49">49</xref>]. Mitochondrial complex I is often the target in neurodegenerative PD since it plays a crucial role in the mitochondrial respiratory chain [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B48">48</xref>].</p>
</sec>
<sec id="sec4">
<title>4. Parkinson's Disease Animal Models: Rodents versus Zebrafish</title>
<p>Recent studies showed that mitochondrial dysfunction is a key feature of PD pathogenesis [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. According to numerous reports, there are several chemical compounds which could influence the activity of mitochondrial complex I. In this way, the modulation of mitochondrial activity could lead to the occurrence of PD-like symptomatology in both rodent and zebrafish models. Thus, rotenone, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat, 6-hydroxydopamine (6-OHDA), pyrethroids, and organophosphates [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B51">51</xref>–<xref ref-type="bibr" rid="B53">53</xref>] were successfully used to increase the ROS levels and therefore to promote dopaminergic neuron degeneration [<xref ref-type="bibr" rid="B54">54</xref>]. This could be the reason why many PD animal models (mainly rodents) are based on the acute/chronic administration of some of the mentioned chemicals and also the evidence which ties OS to PD molecular pathways. <xref ref-type="table" rid="tab1"> Table 1</xref> summarises several animal model studies on PD-like impairments, chemical inductors, and comparisons between the zebrafish and rodent models.</p>
<p>Accumulation of <italic>α</italic>-syn is a clear sign of PD and one of the main causes to its development [<xref ref-type="bibr" rid="B73">73</xref>]. Synucleins, a family of proteins naturally occurring in the nervous system, are known to contribute to vesicle synapse maintenance or DA activity [<xref ref-type="bibr" rid="B65">65</xref>–<xref ref-type="bibr" rid="B68">68</xref>]. Zebrafish possesses three genes which encode <italic>β</italic>-, <italic>γ</italic>1-, and <italic>γ</italic>2-synucleins [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Milanese et al. [<xref ref-type="bibr" rid="B14">14</xref>] showed that if the <italic>β</italic>- and <italic>γ</italic>1-synucleins are knocked out, zebrafish exhibits hypokinesia and low levels of DA. Zebrafish synucleins (zSynC) share a high similarity with human synucleins, wherein zSynC is 70% identical and 82% similar to human <italic>β</italic>-synuclein [<xref ref-type="bibr" rid="B74">74</xref>].</p>
<p>Furthermore, Prabhudesai et al. [<xref ref-type="bibr" rid="B75">75</xref>] suggested that <italic>α</italic>-syn accumulation in the zebrafish nervous system leads to neuron apoptosis and death. Their hypothesis was confirmed since CLR01, a molecular tweezer, could increase the survival rate of embryos and suppress <italic>α</italic>-syn aggregation in a transgenic zebrafish model carrying human wild type <italic>α</italic>-syn [<xref ref-type="bibr" rid="B75">75</xref>].</p>
<p>Previous studies demonstrated that overexpression of <italic>α</italic>-syn in a hypothalamic neuronal cell line could lead to increased ROS, mitochondrial impairment, and LB [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B76">76</xref>]. Also, it was suggested that cholesterol metabolites resulting from ROS degradation could promote the aggregation of <italic>α</italic>-syn [<xref ref-type="bibr" rid="B76">76</xref>].</p>
<p>Due to several limitations of the classical chemical-inducing animal models, genetically engineered animal models are now generally preferred. However, the studies on the pathological mechanisms underlying PD development consider more appropriate the use of the chemical-inducing models, since the interplay between the dopaminergic neuron functions and brain redox activity remains a fine game of regulatory potentials. Thus, the study of OS was performed on animal models, such as <italic>Drosophila</italic>, zebrafish, mice, or rats, predominantly using common neurotoxicants (MPTP, 6-OHDA, rotenone, and paraquat) [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B78">78</xref>]. Thus, the main mechanisms related to Parkinson's disease in the zebrafish central nervous system are schematically presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>, together with several agents that induce Parkinson's disease and some treatment alternatives.</p>
</sec>
<sec id="sec5">
<title>5. MPTP</title>
<p>One of the most common chemical agents which can modulate PD symptomatology in animal models is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B83">83</xref>]. Following its monoamine oxidase B (MAO-B) promoted conversion to 1-methyl-4-phenylpyridinium in astrocytes [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B56">56</xref>], MPP<sup>+</sup> could easily bind DA transporters reaching mitochondria and interfering in the oxidative phosphorylation process carried out by mitochondrial complex I [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B84">84</xref>]. Also, many reports described the MPTP neurotoxicity to be correlated with tyrosine hydrolase loss and DA transporters [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. Due to the fact that the participants to this mechanism are highly conserved, OS induction in this way was observed in zebrafish, mice, rats, cats, dogs, and nonhuman primates [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B85">85</xref>].</p>
<p>In zebrafish, the reports showed that MPTP could efficiently induce decreased locomotor activity, which is caused by DA activity decrease, number of DA neurons, and pretectal size reduction [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B86">86</xref>–<xref ref-type="bibr" rid="B88">88</xref>]. Also, MPTP could induce bradykinesia manifested in zebrafish as decreased velocity and abnormal swimming behaviour [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B89">89</xref>]. Moreover, as compared to rodent models which seemed to overcome the short-term toxin activity on locomotion or even exhibit no changes or hyperactivity [<xref ref-type="bibr" rid="B90">90</xref>], zebrafish showed behavioural changes even in acute MPTP administration (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
<p>However, neuromodulation efficiency depends on several factors, such as the administration route, sex, strain, and developmental stage [<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B91">91</xref>]. For example, larval zebrafish is more sensitive to MPTP than adult zebrafish [<xref ref-type="bibr" rid="B92">92</xref>]. Also, Jackson-Lewis et al. [<xref ref-type="bibr" rid="B93">93</xref>] showed that MPTP administration effects could be influencing the size of central nervous system damage in a dose-dependent manner, since they demonstrated that the impairment of tyrosine hydroxylase (TH) activity following lower doses of MPTP could not lead to DA neuron loss in mice. Thus, Kirchhoff et al. [<xref ref-type="bibr" rid="B94">94</xref>] reported that two MPTP injections (15 or 20 mg/kg) for 7 consecutive days were sufficient to cause dopaminergic neuron loss in mice. Thus, in a recent report of Mingazov et al. [<xref ref-type="bibr" rid="B95">95</xref>], it was demonstrated that 12 mg/kg b.w./day subcutaneous MPTP treatment for 2 weeks could not induce DA metabolism impairment or MAO-A and MAO-B enzyme activity changes even with DA neuron loss confirmation.</p>
<p>Similarly, the reports on DA neuron loss in zebrafish are rather controversial. In this way, it was shown that at 24 hours postfertilization, zebrafish embryos immersed in MPTP solution (800 <italic>μ</italic>M, distilled water) for 2 days exhibited posterior tuberculum DA neuron function impairment leading to behavioural deficits [<xref ref-type="bibr" rid="B96">96</xref>]. Also, since L-deprenyl treatment—which is a potent MAO-B inhibitor—could prevent neurodegeneration in zebrafish [<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B97">97</xref>], it could be suggested that a similar mammalian MPTP catabolism pathway could be present in zebrafish; however, it is a known fact that they possess a single monoamine oxidase homologous to both MAO-A and MAO-B [<xref ref-type="bibr" rid="B55">55</xref>].</p>
<p>In this way, despite the demonstrated limitations of the rodent models, mice are preferred for DA neuron loss models, since there is no previous report accounting for the neuronal loss that was not present after MPTP administration in mice and rats.</p>
</sec>
<sec id="sec6">
<title>6. 6-OHDA</title>
<p>Because it is incapable of passing the blood-brain barrier, the catecholamine 6-hydroxydopamine (6-OHDA) was the first neurotoxin used to model PD [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B98">98</xref>] by direct/sham injection [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>]. The 6-OHDA mechanism of action consists of mitochondrial complex I and IV inhibition [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B100">100</xref>–<xref ref-type="bibr" rid="B102">102</xref>] and also autoxidation resulting in O<sub>2</sub><sup>−</sup> and H<sub>2</sub>O<sub>2</sub>. In this way, the major effect of 6-OHDA is the DA neuron impairment.</p>
<p>Regarding the active potential of 6-OHDA to model PD symptomatology in zebrafish, it was observed that its administration could lead to changes in both biochemical and behavioural parameters. In this way, several studies reported that the 6-OHDA administration led to a decrease in dopamine and noradrenaline levels and also suggested that OS could develop in a cause-effect relationship with regard to 6-OHDA [<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Furthermore, it seems that 6-OHDA could successfully model in zebrafish one of the main PD symptoms—motor disturbances—as it was previously suggested that zebrafish larvae exposed to a 6-OHDA solution exhibited salient motor impairments and decreases in tyrosine hydroxylase activity [<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B80">80</xref>–<xref ref-type="bibr" rid="B82">82</xref>].</p>
<p>Also, the other PD hallmark symptom—DA neuron loss—was evaluated in zebrafish models by Parng et al. [<xref ref-type="bibr" rid="B103">103</xref>] and Vijayanathan et al. [<xref ref-type="bibr" rid="B48">48</xref>]. Thus, they showed that irrespective of the administration route and developmental stage (e.g., Parng et al. treated zebrafish embryos with 250 <italic>μ</italic>M 6-OHDA dissolved in the water, while, Vijayanathan et al. microinjected 25 mg/kg 6-OHDA in the ventral diencephalon of adult zebrafish), 6-OHDA treatment as short as 3 days could lead to DA neuron loss [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B103">103</xref>].</p>
<p>Moreover, given the many differences between zebrafish and rodents, similar effects of 6-OHDA administration were reported in rodent models [<xref ref-type="bibr" rid="B101">101</xref>]. Also, regarding the OS implications of 6-OHDA in rodent models, the antioxidant role of GPx overexpression and thus an increase in activity for the DA neuron protection was demonstrated. In this way, Bensadoun et al. [<xref ref-type="bibr" rid="B104">104</xref>] suggested that one of the most prominent components of the anti-6-OHDA neurotoxic effect is the GPx antioxidant enzyme which not only prevented the dopamine secretion inhibition but also indirectly modulated the tyrosine hydroxylase activity.</p>
</sec>
<sec id="sec7">
<title>7. Rotenone</title>
<p>Despite that MPTP and 6-OHDA administrations are one of the most common ways to modulate PD symptomatology in animal models, more recent research revealed that several nonintended molecules possess the potential to induce PD [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B105">105</xref>]. For example, exposure to some extensively used herbicides and pesticides was shown to lead to mitochondrial dysfunction and DA neuron loss. In this category stands rotenone, which is an alkaloidal pesticide used worldwide [<xref ref-type="bibr" rid="B106">106</xref>] and which acts on mitochondrial complex I and DA neurons [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B106">106</xref>–<xref ref-type="bibr" rid="B109">109</xref>]. According to Alam and Schmidt's report [<xref ref-type="bibr" rid="B17">17</xref>], rotenone could destroy DA neurons and induce PD symptomatology in rats following 2 months of intraperitoneal treatment. Also, it was shown that rotenone administration could lead to <italic>α</italic>-syn aggregate formation and increased oxidant levels [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B64">64</xref>–<xref ref-type="bibr" rid="B67">67</xref>].</p>
<p>The cytotoxic effects of rotenone seen in fish are similar to those observed in rodents. For example, the administration of rotenone in zebrafish could lead to impaired motor ability, olfactory dysfunction, and decreased DA levels [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B110">110</xref>]. Also, DA neuron reduction was reported by Martel et al.'s study [<xref ref-type="bibr" rid="B111">111</xref>], wherein zebrafish embryos received for 7 days a dose of 30 <italic>μ</italic>M rotenone. These aspects were previously described to be a part of the natural mechanism of action of rotenone used to eradicate pests. Moreover, the OS-causing potential of rotenone was described and additional evidence was brought by Melo et al. [<xref ref-type="bibr" rid="B112">112</xref>] who demonstrated that 20 <italic>μ</italic>g l<sup>−1</sup> rotenone can inhibit CAT, GST, and acetyl cholinesterase activity.</p>
<p>Another recent report showed that a 4-week administration of 2 <italic>μ</italic>g l<sup>−1</sup> rotenone to adult zebrafish leads to 40-50% TH expression decrease. Also, the decrease of DA level was correlated with impaired locomotor activity as a motor symptom and anxiety behaviour specific to PD individuals [<xref ref-type="bibr" rid="B110">110</xref>]. As stated before, rotenone is a potent tool to induce motor and nonmotor symptoms of PD in a zebrafish model [<xref ref-type="bibr" rid="B111">111</xref>, <xref ref-type="bibr" rid="B112">112</xref>].</p>
</sec>
<sec id="sec8">
<title>8. Paraquat</title>
<p>Being largely used as herbicide, the paraquat mechanism of action is similar to MPTP [<xref ref-type="bibr" rid="B39">39</xref>]. In this way, lipid peroxidation, mitochondrial dysfunction, accumulation of <italic>α</italic>-syn, and low levels of GSH were reported in organism models such as rodents and zebrafish following paraquat administration [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B113">113</xref>]. Additionally, the loss of DA neurons is evidence of the effects of paraquat which can be observed in behavioural and biochemical deficits [<xref ref-type="bibr" rid="B70">70</xref>].</p>
<p>Moreover, it was shown that paraquat has the potential to increase the effect of ROS on other molecules, such as lipids, which are one of the main targets of oxidants [<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B115">115</xref>]. Thus, it was observed that 0.04 ppm paraquat administration to zebrafish could lead to more than a 15% increase in MDA levels after 96 hours, concomitantly with DA, GSH, and serotonin decrease [<xref ref-type="bibr" rid="B79">79</xref>]. Another important aspect on the paraquat mechanism of action in zebrafish models was that intraperitoneal administration could lead to increased CAT and GPx activity suggesting that its administration could boost some of the antioxidant enzyme activities in the effort of decreasing the cellular ROS levels [<xref ref-type="bibr" rid="B116">116</xref>].</p>
</sec>
<sec id="sec9">
<title>9. Relevant Antioxidant Opportunities in Parkinson's Disease Treatment</title>
<p>Considering that healthy functioning metabolism includes a physiological anti-ROS system actively engaged in the prevention of overproduction and accumulation of ROS and that OS seems to be an important component of PD in both human and animal models, the obvious lead for a PD cure could be the antioxidant system stimulation. In this way, the antioxidant system consists of biologically active molecules responsible for ROS neutralization and cell protection against the free toxic radicals' effects [<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B7">7</xref>]. Thus, the antioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), and glutathione reductase (GRx) [<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B13">13</xref>], and the nonenyzmatic antioxidants, such as lipoic acid, coenzyme Q10, melatonin, vitamin E, vitamin C, flavonoids, and omega acids [<xref ref-type="bibr" rid="B21">21</xref>], form a powerful protection system which prevents the occurrence of OS.</p>
<p>Regarding the implication of mitochondria in ROS metabolism, being responsible for adenosine triphosphate (ATP) production, the main chemical energy source for cellular functions [<xref ref-type="bibr" rid="B23">23</xref>], it was demonstrated that the reduction of the ATP synthesis and the electron transport chain impairments lead to ROS accumulation [<xref ref-type="bibr" rid="B24">24</xref>]. Due to the fact that mitochondria are a high-quantity ROS source, the correlation between mitochondrial dysfunction and neurodegenerative diseases was predictable. Moreover, the biochemical profile of the brain and the vital role of ROS in brain molecular signalling are further evidence that the central nervous system is continuously predisposed to OS exposure [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. Additional evidence regarding the antioxidant system and the modulatory pathways has been reported while studying antioxidant supplements, while it was observed that they could provide symptomatology relief or even to reverse oxidative changes and their effects in chronic mitochondrial diseases [<xref ref-type="bibr" rid="B24">24</xref>].</p>
<p>PD treatment is mainly based on levodopa and dopamine agonists (amantadine) [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B118">118</xref>]. Despite the advantages of levodopa administration, dopamine agonists only partially reverse motor symptoms of PD leading to different motor oscillations. However, levodopa remains the main substance used in PD therapy [<xref ref-type="bibr" rid="B117">117</xref>–<xref ref-type="bibr" rid="B119">119</xref>].</p>
<p>Also, other alternatives for PD treatment are catechol-O-methyl-transferase (COMT) inhibitors and monoamine oxidase B inhibitors, such as safinamide or rasagiline [<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B120">120</xref>, <xref ref-type="bibr" rid="B121">121</xref>]. Similarly, <italic>α</italic>-lipoic acid is used to remove the excess metals, and coenzyme Q10 is used to decrease oxidative marker activity [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B114">114</xref>]. Another efficient therapeutic choice in PD treatment is selegine (L-deprenyl) [<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B122">122</xref>]. The carotenoid lycopene was described as a potent antioxidant by reducing the complex I inhibition in a rotenone rat model and reversing MPTP effects in a PD mice model [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B123">123</xref>].</p>
<p>Besides the drug-centred therapies, exercise programs are an effective strategy used in PD patients to improve and to delay functional decline [<xref ref-type="bibr" rid="B124">124</xref>]. Alongside the improvement in muscle tonus, it was demonstrated that exercise leads to OS decrease and overall metabolism improvement [<xref ref-type="bibr" rid="B125">125</xref>], while muscle weakness is one of the main symptoms of PD, its severity increasing with time [<xref ref-type="bibr" rid="B126">126</xref>]. Despite that several studies reported muscle weakness as a consequence of sedentary state and aging processes, bradykinesia seems an important and independent symptom of PD; however, its occurrence mechanism is not fully understood [<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B126">126</xref>]. Recently, it was demonstrated that aquatic exercise therapy could improve motor disability of PD individuals [<xref ref-type="bibr" rid="B127">127</xref>].</p>
<p>Studies made until now using animal models led to new speculations regarding PD treatment and other alternatives for it. Treatment with 100 <italic>μ</italic>M vitamin E, 10 <italic>μ</italic>M minocycline, and 25 <italic>μ</italic>g/ml Sinemet (a well-known drug for PD which contains carbidopa and levodopa) in the presence of 25 <italic>μ</italic>g/ml 6-OHDA of zebrafish larvae led to a reverse of locomotor disruptions and of the changes that appeared for parkin, pink1, and cd-11b mRNA expression [<xref ref-type="bibr" rid="B80">80</xref>]. Locomotor deficits and neuronal loss observed in zebrafish larvae after 3 days of treatment with 250 <italic>μ</italic>M 6-OHDA were prevented by 10 <italic>μ</italic>M minocycline and 1 <italic>μ</italic>M rasagiline coadministration [<xref ref-type="bibr" rid="B81">81</xref>]. Another study also reported motor and optomotor alterations and morphological changes in zebrafish larvae induced by 250 <italic>μ</italic>M 6-OHDA which were ameliorated after supplementation with 1 mg l<sup>−1</sup> N-acetylcysteine, which is known for its antioxidant, anti-inflammatory, and neurotrophic potential [<xref ref-type="bibr" rid="B82">82</xref>].</p>
</sec>
<sec id="sec10">
<title>10. Is There an Oxidative Stress Correlation to Sleep Disturbances in Parkinson's Disease?</title>
<p>According to Porkka-Heiskanen et al. [<xref ref-type="bibr" rid="B128">128</xref>], sleep is the periodic physiological state characterized by temporal suppression of consciousness, partial loss of sensitivity, and decrease of several body functions, such as heart rhythm, respiratory rate, muscle relaxation, and body temperature. Due to its complex mechanism, many factors influence the quantity and quality of sleep, namely stress exposure, health conditions, or some forms of substance abuse [<xref ref-type="bibr" rid="B128">128</xref>].</p>
<p>Several recent studies reported that sleep disturbances are a common symptom of PD. In this way, both Menza et al. [<xref ref-type="bibr" rid="B129">129</xref>] and Selvaraj and Keshavamurthy [<xref ref-type="bibr" rid="B130">130</xref>] described that a direct correlation between PD severity and sleeping time could be suggested and assumed by memory deficits, depressive mood, body weakness, and involuntary sleep events during the day [<xref ref-type="bibr" rid="B128">128</xref>]. In this way, several sleep disturbances were described to occur in PD patients, such as insomnia, sleep-related respiratory disorders (SRD), excessive daytime sleepiness (EDS), and sleep-related motor problems often exhibited with variable intensities and durations [<xref ref-type="bibr" rid="B129">129</xref>–<xref ref-type="bibr" rid="B131">131</xref>]. The connection between these sleep impairments and PD could be certain mechanisms also occurring in OS, for an instance due to sleep apnea or poor oxygenation of the brain during sleeping time [<xref ref-type="bibr" rid="B132">132</xref>].</p>
<p>However, regarding the occurrence of sleep-related respiratory symptoms in PD patients, recent studies reported controversial results. In this way, sleep apnea episodes were not significantly present in PD patients, as compared to control groups [<xref ref-type="bibr" rid="B131">131</xref>], despite that other reports demonstrated that almost 50% of PD patients experienced sleep apnea incidents [<xref ref-type="bibr" rid="B129">129</xref>]. In a more recent study, Bohnen and Hu [<xref ref-type="bibr" rid="B132">132</xref>] reported a correlation between sleep apnea which leads to repeated periods of hypoxia and reoxygenation during sleeping and the occurrence of OS and inflammation though a similar mechanism with sleep apnea-induced chronic intermittent hypoxia models. On the other hand, other studies reported that the more common sleep disturbance in PD patients is insomnia [<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B133">133</xref>], which is present in 54-60% of cases [<xref ref-type="bibr" rid="B134">134</xref>]. However, Gjerstad et al. [<xref ref-type="bibr" rid="B134">134</xref>] discussed the results in the context of age, pathological lesions in the upper brainstem and midbrain, depression, nocturia, and medication [<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B135">135</xref>]. Thus, the multifactorial etiology of sleep disturbances [<xref ref-type="bibr" rid="B132">132</xref>] could be discussed in this context and also in the context of the possible comorbidity of sleep disturbances in PD. However, the cause-effect relationship between PD and sleep disturbances is not fully understood.</p>
<p>Another PD-occurring sleep disturbance is rapid eye movement sleep behaviour disorder characterized by motor behaviours and different vocalizations [<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B136">136</xref>]. By comparison with the other sleep disturbance symptoms in PD, rapid eye movement sleep behaviour disorder is being considered a premotor symptom, and in some cases a disease development marker [<xref ref-type="bibr" rid="B137">137</xref>] due to the fact that 40 to 65% of those diagnosed with rapid eye movement sleep behaviour disorder are further later diagnosed with PD [<xref ref-type="bibr" rid="B137">137</xref>–<xref ref-type="bibr" rid="B140">140</xref>]. Excessive daytime sleepiness (EDS) and fatigue are also present in PD [<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. Restless legs syndrome (RLS) and periodic limb movements in sleep (PLMS) are both correlated to PD [<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B143">143</xref>, <xref ref-type="bibr" rid="B144">144</xref>].</p>
<p>RLS is a sensorimotor condition characterized by the desire to move the legs due to unpleasant sensations [<xref ref-type="bibr" rid="B133">133</xref>]. Often appearing in older PD patients, RLS was correlated to iron deficiency as a secondary condition for RLS onset [<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>]. However, low substantia nigra iron levels were reported in RLS while increased iron levels in PD patients were suggested to lead to OS [<xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>]. Both PD and RLS are characterized by iron deficiency, which may lead to DA damage specific for PD-RLS according to a study published in 2017 [<xref ref-type="bibr" rid="B142">142</xref>].</p>
<p>The correlation between OS and PD was previously described, but so was the idea that sleep deprivation can cause OS [<xref ref-type="bibr" rid="B146">146</xref>–<xref ref-type="bibr" rid="B148">148</xref>]. Thus, it is controversial to ask if any of these correlations could be explained in the context of the presence of all three components: PD, sleep disturbance, and OS. This aspect was partly elucidated due to animal models using certain substances or genetic manipulations for PD features. Scientific literature reported various ways to study these aspects whose target were sleep disturbances [<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B130">130</xref>]. Disruptions in diurnal rhythms, stress, and specific alterations in sleep architecture are only three examples of methods used in animal research [<xref ref-type="bibr" rid="B149">149</xref>].</p>
<p>In this way, a recent study presented reasonable evidence which correlated sleep disorders occurring in PD and OS. Filograna et al. [<xref ref-type="bibr" rid="B150">150</xref>] extensively described the mechanism through which iron chelators prevent the increase of substantia nigra iron levels in PD patients. Thus, in a well-known study, an iron-chelator-treated chronic iron-loaded mice model exhibited improved OS markers and decreased iron levels. Also, the same group described the antioxidant effects of melatonin in the context of PD-occurring OS mechanisms. The authors pointed out that melatonin antioxidant activity is not described as only free radicals scavenging, but also as other indirect modulatory activities, such as expression stimulation of several antioxidant enzymes and the downregulation of prooxidant enzymes.</p>
<p>Another important component of this triad is the mechanism underlying intermittent hypoxemia observed in PD patients in concomitance with obstructive sleep apnea [<xref ref-type="bibr" rid="B151">151</xref>]. According to Kaminska et al. [<xref ref-type="bibr" rid="B151">151</xref>], a potential origin of OS occurrence in PD would be the exposure to intermittent episodes of hypoxemia during the sleeping periods. It was shown that intermittent hypoxemia could lead to important changes in the brain structures involved in peripheral nerve conduction, impaired learning and memory, and neuronal loss possibly through mechanisms of ischemia/reperfusion, and oxidative injury.</p>
<p>The recent report of Cao et al. [<xref ref-type="bibr" rid="B152">152</xref>] suggested that another OS-related ion could be involved in sleep disturbances. It was demonstrated that magnesium could have long-term benefits in reducing the likelihood of falling asleep in the daytime in women, but not in men, through a mechanism that is, however, unknown. Genetic predisposition would be one of the possible responses in the matter of mechanisms.</p>
<p>Despite that the genetic landscape of PD is currently well described, the implication of magnesium in PD has been only recently hypothesised [<xref ref-type="bibr" rid="B153">153</xref>]. Recent research in human and animal models showed that low magnesium levels are correlated with increased risk to develop PD [<xref ref-type="bibr" rid="B154">154</xref>]. Moreover, Sturgeon et al. [<xref ref-type="bibr" rid="B154">154</xref>] suggested that the mechanism through which this correlation is built is based on a unique genetic landscaping of magnesium homeostasis. Sustaining this hypothesis, several studies meta-analysed by Jin et al. [<xref ref-type="bibr" rid="B155">155</xref>] suggested that increased magnesium levels are a molecular feature of PD, therefore magnesium dishomeostasis may be considered a real risk factor in PD. Both SLC41A1 and TRPM7 are directly or indirectly modulating sleep-related behaviours [<xref ref-type="bibr" rid="B154">154</xref>]. Thus, SLC41A1 is being involved in rapid eye movement sleep behaviour disorder [<xref ref-type="bibr" rid="B156">156</xref>], while TRPM7 is suggested to be involved in sleep-wake cycle modulation through magnesium ion ligation potential [<xref ref-type="bibr" rid="B157">157</xref>].</p>
<p>Moreover, the OS and DA perturbations were also observed in gene mutations of <italic>α</italic>-syn, PINK, parkin, and DJ-1 proteins [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B52">52</xref>]. The lack of PINK1 leads to a loss of DA neurons, affects the mitochondrial morphology, and is linked with OS [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B158">158</xref>–<xref ref-type="bibr" rid="B161">161</xref>]. Also, the accumulation of <italic>α</italic>-syn causes the reduction of mitochondrial activity and a high production of ROS which is completed by cell death [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. The PARK2 and LRRK2 genes represent a source of ROS production [<xref ref-type="bibr" rid="B26">26</xref>]. All these proteins are linked with PD pathogenesis, and their use in genetic manipulations has become a new tool in transgenic animal models [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B161">161</xref>, <xref ref-type="bibr" rid="B162">162</xref>].</p>
<p>Thus, genetic implications in PD are not new to PD research. Several recent studies suggested not only that some genetic factors give real predisposition to PD development at some point in life [<xref ref-type="bibr" rid="B163">163</xref>] but also that PD may be one of the disorders which run in a family [<xref ref-type="bibr" rid="B164">164</xref>]. Currently, more than 20 PD genetic predisposition loci are identified and extensively reviewed [<xref ref-type="bibr" rid="B163">163</xref>]. Among these, some target the synaptic vesicle anomalies (SNCA mutations), the protein-to-protein interaction in the cytoskeleton assembly (dardarin gene mutations), ubiquitin degradation (parkin gene mutations), and several other energetic mechanisms.</p>
</sec>
<sec id="sec11">
<title>11. Conclusions</title>
<p>This study synthesized the current information and correlated available data on the relevance of the oxidative stress status modifications in the complex pathophysiology of Parkinson's disease with regard to the available animal models. Moreover, the importance of the zebrafish model in Parkinson's disease research was described. It was observed that OS possesses an important role in Parkinson's disease as shown by numerous animal model studies, many of which are based on rodent experimental models. However, an emerging impact of the zebrafish model was observed in research on Parkinson's disease pathological mechanisms with regard to disease development factors, cause-effect relationship of oxidative stress and comorbidities (such as depression, hyposmia, fatigue, sleep disturbances, and cognitive deficits), and also regarding the pharmacological potential of antioxidant molecules in Parkinson's disease treatment.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>AC and IMB are supported by a research grant for Young Teams offered by UEFISCDI, Romania, no. PN-III-P1-1.1-TE-2016-1210, contract no. 58 from 02/05/2018, called “Complex study regarding the interactions between OS, inflammation and neurological manifestations in the pathophysiology of irritable bowel syndrome (animal models and human patients).” MAR was funded by the European Social Fund, through Operational Programme Human Capital 2014-2020, project number POCU/380/6/13/123623, project title “PhD Students and Postdoctoral Researchers Prepared for the Labour Market!”.</p>
</ack>
<sec sec-type="COI-statement">
<title>Conflicts of Interest</title>
<p>None, except for the research grants mentioned in the Acknowledgments.</p>
</sec>
<sec>
<title>Authors' Contributions</title>
<p>Robea M.-A. and Balmus I.-M. equally contributed to this work as first authors.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sies</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berndt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D. P.</given-names>
</name>
</person-group>
<article-title>Oxidative stress</article-title>
<source/>
<italic toggle="yes">Annual Review of Biochemistry</italic>
<year>2017</year>
<volume>86</volume>
<issue>1</issue>
<fpage>715</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-biochem-061516-045037</pub-id>
<pub-id pub-id-type="other">2-s2.0-85009852867</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cenini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lloret</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view</article-title>
<source/>
<italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic>
<year>2019</year>
<volume>2019</volume>
<fpage>18</fpage>
<pub-id pub-id-type="publisher-id">2105607</pub-id>
<pub-id pub-id-type="doi">10.1155/2019/2105607</pub-id>
<pub-id pub-id-type="other">2-s2.0-85068414403</pub-id>
<pub-id pub-id-type="pmid">31210837</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aboul-Enein</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Kładna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bowser</surname>
<given-names>J. E.</given-names>
</name>
</person-group>
<article-title>Oxidative stress in biological systems and its relation with pathophysiological functions: the effect of physical activity on cellular redox homeostasis</article-title>
<source/>
<italic toggle="yes">Free Radical Research</italic>
<year>2019</year>
<volume>53</volume>
<issue>5</issue>
<fpage>497</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2019.1612059</pub-id>
<pub-id pub-id-type="other">2-s2.0-85066041285</pub-id>
<pub-id pub-id-type="pmid">31039624</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salim</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and psychological disorders</article-title>
<source/>
<italic toggle="yes">Current Neuropharmacology</italic>
<year>2014</year>
<volume>12</volume>
<issue>2</issue>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.2174/1570159x11666131120230309</pub-id>
<pub-id pub-id-type="other">2-s2.0-84896348093</pub-id>
<pub-id pub-id-type="pmid">24669208</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Noreen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Castro-Gomes</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mohammadzai</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Batista Teixeira da Rocha</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Landeira-Fernandez</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Association of oxidative stress with psychiatric disorders</article-title>
<source/>
<italic toggle="yes">Current Pharmaceutical Design</italic>
<year>2016</year>
<volume>22</volume>
<issue>20</issue>
<fpage>2960</fpage>
<lpage>2974</lpage>
<pub-id pub-id-type="doi">10.2174/1381612822666160307145931</pub-id>
<pub-id pub-id-type="other">2-s2.0-84984585818</pub-id>
<pub-id pub-id-type="pmid">26951103</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polito</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Seripa</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Genetic profile, environmental exposure, and their interaction in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Parkinson's Disease</italic>
<year>2016</year>
<volume>2016, article 6465793</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1155/2016/6465793</pub-id>
<pub-id pub-id-type="other">2-s2.0-84959449135</pub-id>
<pub-id pub-id-type="pmid">26942037</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zwicker</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness</article-title>
<source/>
<italic toggle="yes">World Psychiatry</italic>
<year>2017</year>
<volume>16</volume>
<issue>2</issue>
<fpage>121</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20436</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019207628</pub-id>
<pub-id pub-id-type="pmid">28498595</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Culp</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Craver</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Darley-Usmar</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2018</year>
<volume>144</volume>
<issue>6</issue>
<fpage>691</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.14308</pub-id>
<pub-id pub-id-type="other">2-s2.0-85042086918</pub-id>
<pub-id pub-id-type="pmid">29341130</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Okun</surname>
<given-names>M. S.</given-names>
</name>
</person-group>
<article-title>Diagnosis and treatment of Parkinson Disease</article-title>
<source/>
<italic toggle="yes">JAMA</italic>
<year>2020</year>
<volume>323</volume>
<issue>6</issue>
<fpage>548</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2019.22360</pub-id>
<pub-id pub-id-type="pmid">32044947</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Gasser</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>DeLong</surname>
<given-names>M. R.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Zigmond</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>L. P.</given-names>
</name>
</person-group>
<person-group person-group-type="author">
<name>
<surname>Coyle</surname>
<given-names>B. D.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Chapter 19. Parkinson disease and other synucleinopathies</italic>
<year>2015</year>
<publisher-loc>San Diego</publisher-loc>
<publisher-name>Academic Press</publisher-name>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Kouli</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Torsney</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kuan</surname>
<given-names>K. M.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Stoker</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Greenland</surname>
<given-names>T. B.</given-names>
</name>
</person-group>
<article-title>Parkinson’s disease: etiology, neuropathology, and pathogenesis</article-title>
<source/>
<italic toggle="yes">Parkinson’s Disease: Pathogenesis and Clinical Aspects</italic>
<year>2018</year>
<publisher-name>Codon Publications</publisher-name>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Noble</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ekker</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Modeling neurodegeneration in zebrafish</article-title>
<source/>
<italic toggle="yes">Current Neurology and Neuroscience Reports</italic>
<year>2011</year>
<volume>11</volume>
<issue>3</issue>
<fpage>274</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1007/s11910-011-0182-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-79961143031</pub-id>
<pub-id pub-id-type="pmid">21271309</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennan</surname>
<given-names>C. H.</given-names>
</name>
</person-group>
<article-title>Zebrafish behavioural assays of translational relevance for the study of psychiatric disease</article-title>
<source/>
<italic toggle="yes">Reviews in the Neurosciences</italic>
<year>2011</year>
<volume>22</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1515/RNS.2011.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-79960141266</pub-id>
<pub-id pub-id-type="pmid">21615260</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milanese</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sager</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypokinesia and reduced dopamine levels in zebrafish lacking <italic>β</italic>- and <italic>γ</italic>1-Synucleins</article-title>
<source/>
<italic toggle="yes">The Journal of Biological Chemistry</italic>
<year>2012</year>
<volume>287</volume>
<issue>5</issue>
<fpage>2971</fpage>
<lpage>2983</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.308312</pub-id>
<pub-id pub-id-type="other">2-s2.0-84856250576</pub-id>
<pub-id pub-id-type="pmid">22128150</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betarbet</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sherer</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>MacKenzie</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Garcia-Osuna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Panov</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Greenamyre</surname>
<given-names>J. T.</given-names>
</name>
</person-group>
<article-title>Chronic systemic pesticide exposure reproduces features of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Nature Neuroscience</italic>
<year>2000</year>
<volume>3</volume>
<issue>12</issue>
<fpage>1301</fpage>
<lpage>1306</lpage>
<pub-id pub-id-type="doi">10.1038/81834</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033681149</pub-id>
<pub-id pub-id-type="pmid">11100151</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khotimah</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sumitro</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Widodo</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>Decreasing <italic>α</italic>-synuclein aggregation by methanolic extract of _Centella asiatica_ in zebrafish Parkinson's model</article-title>
<source/>
<italic toggle="yes">Asian Pacific Journal of Tropical Biomedicine</italic>
<year>2015</year>
<volume>5</volume>
<issue>11</issue>
<fpage>948</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1016/j.apjtb.2015.07.024</pub-id>
<pub-id pub-id-type="other">2-s2.0-84952872319</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>W. J.</given-names>
</name>
</person-group>
<article-title>Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats</article-title>
<source/>
<italic toggle="yes">Behavioural Brain Research</italic>
<year>2002</year>
<volume>136</volume>
<issue>1</issue>
<fpage>317</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1016/s0166-4328(02)00180-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037126181</pub-id>
<pub-id pub-id-type="pmid">12385818</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santoriello</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zon</surname>
<given-names>L. I.</given-names>
</name>
</person-group>
<article-title>Hooked! Modeling human disease in zebrafish</article-title>
<source/>
<italic toggle="yes">The Journal of Clinical Investigation</italic>
<year>2012</year>
<volume>122</volume>
<issue>7</issue>
<fpage>2337</fpage>
<lpage>2343</lpage>
<pub-id pub-id-type="doi">10.1172/JCI60434</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863557893</pub-id>
<pub-id pub-id-type="pmid">22751109</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>A. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2005</year>
<volume>93</volume>
<issue>1</issue>
<fpage>94</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03000.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-20144386944</pub-id>
<pub-id pub-id-type="pmid">15773909</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dagdelen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akkaya</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Genc</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>P.1.g.015 The role of valproic acid and levodopa on oxidative stress in a 6-hydroxydopamine lesioned rat model of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">European Neuropsychopharmacology</italic>
<year>2013</year>
<volume>23</volume>
<fpage>p. S197</fpage>
<pub-id pub-id-type="doi">10.1016/s0924-977x(13)70302-x</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Junn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mouradian</surname>
<given-names>M. M.</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Journal of Parkinson's Disease</italic>
<year>2013</year>
<volume>3</volume>
<issue>4</issue>
<fpage>461</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.3233/jpd-130230</pub-id>
<pub-id pub-id-type="other">2-s2.0-84891645843</pub-id>
<pub-id pub-id-type="pmid">24252804</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nistico</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mehdawy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Piccirilli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mercuri</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Paraquat- and rotenone-induced models of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">International journal of immunopathology and pharmacology</italic>
<year>2011</year>
<volume>24</volume>
<issue>2</issue>
<fpage>313</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1177/039463201102400205</pub-id>
<pub-id pub-id-type="other">2-s2.0-80051739618</pub-id>
<pub-id pub-id-type="pmid">21658306</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blandini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Armentero</surname>
<given-names>M.-T.</given-names>
</name>
</person-group>
<article-title>Animal models of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">The FEBS Journal</italic>
<year>2012</year>
<volume>279</volume>
<issue>7</issue>
<fpage>1156</fpage>
<lpage>1166</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08491.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84859108554</pub-id>
<pub-id pub-id-type="pmid">22251459</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sies</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Oxidative stress: a concept in redox biology and medicine</article-title>
<source/>
<italic toggle="yes">Redox Biology</italic>
<year>2015</year>
<volume>4</volume>
<fpage>180</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1016/j.redox.2015.01.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-84920903716</pub-id>
<pub-id pub-id-type="pmid">25588755</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blesa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Trigo-Damas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Quiroga-Varela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jackson-Lewis</surname>
<given-names>V. R.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Frontiers in Neuroanatomy</italic>
<year>2015</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fnana.2015.00091</pub-id>
<pub-id pub-id-type="other">2-s2.0-84937910217</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puspita</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>J.-W.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and cellular pathologies in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Molecular Brain</italic>
<year>2017</year>
<volume>10</volume>
<issue>1</issue>
<fpage>p. 53</fpage>
<pub-id pub-id-type="doi">10.1186/s13041-017-0340-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85035784486</pub-id>
<pub-id pub-id-type="pmid">29183391</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolson</surname>
<given-names>G. L.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction and chronic disease: treatment with natural supplements</article-title>
<source/>
<italic toggle="yes">Integrative Medicine: A Clinician's Journal</italic>
<year>2014</year>
<volume>13</volume>
<issue>4</issue>
<fpage>35</fpage>
<lpage>43</lpage>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niedzielska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gawlik</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress in neurodegenerative diseases</article-title>
<source/>
<italic toggle="yes">Molecular Neurobiology</italic>
<year>2016</year>
<volume>53</volume>
<issue>6</issue>
<fpage>4094</fpage>
<lpage>4125</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-015-9337-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-84937675316</pub-id>
<pub-id pub-id-type="pmid">26198567</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poewe</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Seppi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>C. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson disease</article-title>
<source/>
<italic toggle="yes">Nature Reviews Disease Primers</italic>
<year>2017</year>
<volume>3</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id>
<pub-id pub-id-type="other">2-s2.0-85016139358</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.-J.</given-names>
</name>
</person-group>
<article-title>Formation and removal of <italic>α</italic>-Synuclein aggregates in cells exposed to mitochondrial inhibitors</article-title>
<source/>
<italic toggle="yes">The Journal of Biological Chemistry</italic>
<year>2002</year>
<volume>277</volume>
<issue>7</issue>
<fpage>5411</fpage>
<lpage>5417</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.m105326200</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037085288</pub-id>
<pub-id pub-id-type="pmid">11724769</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>A. C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death</article-title>
<source/>
<italic toggle="yes">The Journal of Neuroscience</italic>
<year>2006</year>
<volume>26</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1523/jneurosci.4308-05.2006</pub-id>
<pub-id pub-id-type="other">2-s2.0-30644471051</pub-id>
<pub-id pub-id-type="pmid">16399671</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beitz</surname>
<given-names>J. M.</given-names>
</name>
</person-group>
<article-title>Parkinson s disease a review</article-title>
<source/>
<italic toggle="yes">Frontiers in Bioscience</italic>
<year>2014</year>
<volume>S6</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.2741/s415</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Segura-Aguilar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Paris</surname>
<given-names>I.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Kostrzewa</surname>
<given-names>R. M.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Mechanisms of dopamine oxidation and Parkinson’s disease BT - Handbook of Neurotoxicity</italic>
<year>2014</year>
<publisher-loc>New York, NY</publisher-loc>
<publisher-name>Springer New York</publisher-name>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olanow</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Tatton</surname>
<given-names>W. G.</given-names>
</name>
</person-group>
<article-title>Etiology and pathogenesis of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Annual Review of Neuroscience</italic>
<year>1999</year>
<volume>22</volume>
<issue>1</issue>
<fpage>123</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.22.1.123</pub-id>
<pub-id pub-id-type="other">2-s2.0-0032936755</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Lindenau</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Seyfried</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Glutathione, oxidative stress and neurodegeneration</article-title>
<source/>
<italic toggle="yes">European Journal of Biochemistry</italic>
<year>2000</year>
<volume>267</volume>
<issue>16</issue>
<fpage>4904</fpage>
<lpage>4911</lpage>
<pub-id pub-id-type="doi">10.1046/j.1432-1327.2000.01595.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033899208</pub-id>
<pub-id pub-id-type="pmid">10931172</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halliwell</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Role of free radicals in the neurodegenerative Diseases</article-title>
<source/>
<italic toggle="yes">Drugs &amp; Aging</italic>
<year>2001</year>
<volume>18</volume>
<issue>9</issue>
<fpage>685</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.2165/00002512-200118090-00004</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034796353</pub-id>
<pub-id pub-id-type="pmid">11599635</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciobica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Padurariu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hritcu</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The effects of short-term nicotine administration on behavioral and oxidative stress deficiencies induced in a rat model of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Psychiatria Danubina</italic>
<year>2012</year>
<volume>24</volume>
<issue>2</issue>
<fpage>194</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="pmid">22706419</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asanuma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Neurotoxicity Research</italic>
<year>2003</year>
<volume>5</volume>
<issue>3</issue>
<fpage>165</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1007/bf03033137</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038159674</pub-id>
<pub-id pub-id-type="pmid">12835121</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>S. M.</given-names>
</name>
</person-group>
<article-title>Environmental toxins and Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Annual Review of Pharmacology and Toxicology</italic>
<year>2014</year>
<volume>54</volume>
<issue>1</issue>
<fpage>141</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011613-135937</pub-id>
<pub-id pub-id-type="other">2-s2.0-84891866326</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anichtchik</surname>
<given-names>O. V.</given-names>
</name>
<name>
<surname>Kaslin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peitsaro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Scheinin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Panula</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2004</year>
<volume>88</volume>
<issue>2</issue>
<fpage>443</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02190.x</pub-id>
<pub-id pub-id-type="pmid">14690532</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Kitada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pisani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>D. R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice</article-title>
<volume>104</volume>
<conf-name>Proceedings of the National Academy of Sciences of the United States of America</conf-name>
<conf-date>2007</conf-date>
<issue>27</issue>
<fpage>11441</fpage>
<lpage>11446</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0702717104</pub-id>
<pub-id pub-id-type="other">2-s2.0-34547489872</pub-id>
<pub-id pub-id-type="pmid">17563363</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leibfritz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Moncol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cronin</surname>
<given-names>M. T. D.</given-names>
</name>
<name>
<surname>Mazur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Telser</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Free radicals and antioxidants in normal physiological functions and human disease</article-title>
<source/>
<italic toggle="yes">The International Journal of Biochemistry &amp; Cell Biology</italic>
<year>2007</year>
<volume>39</volume>
<issue>1</issue>
<fpage>44</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2006.07.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-33749986298</pub-id>
<pub-id pub-id-type="pmid">16978905</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Monte</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sandy</surname>
<given-names>M. S.</given-names>
</name>
</person-group>
<article-title>Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage?</article-title>
<source/>
<italic toggle="yes">Annals of Neurology</italic>
<year>1992</year>
<volume>32</volume>
<issue>S1</issue>
<fpage>S111</fpage>
<lpage>S115</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410320719</pub-id>
<pub-id pub-id-type="other">2-s2.0-0026694525</pub-id>
<pub-id pub-id-type="pmid">1510368</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bharath</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rajagopalan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>J. K.</given-names>
</name>
</person-group>
<article-title>Glutathione, iron and Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Biochemical Pharmacology</italic>
<year>2002</year>
<volume>64</volume>
<issue>5–6</issue>
<fpage>1037</fpage>
<lpage>1048</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-2952(02)01174-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036710567</pub-id>
<pub-id pub-id-type="pmid">12213603</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauser</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perlmutter</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Movement Disorders</italic>
<year>2009</year>
<volume>24</volume>
<issue>7</issue>
<fpage>979</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1002/mds.22401</pub-id>
<pub-id pub-id-type="other">2-s2.0-67651148277</pub-id>
<pub-id pub-id-type="pmid">19230029</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Klockgether</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dichgans</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>M. F.</given-names>
</name>
</person-group>
<article-title>The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases</article-title>
<source/>
<italic toggle="yes">Detection of Mitochondrial Diseases</italic>
<year>1997</year>
<fpage>193</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4615-6111-8_30</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A. E.</given-names>
</name>
</person-group>
<article-title>Pharmacological treatment of Parkinson disease: a review</article-title>
<source/>
<italic toggle="yes">JAMA</italic>
<year>2014</year>
<volume>311</volume>
<issue>16</issue>
<fpage>1670</fpage>
<lpage>1683</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2014.3654</pub-id>
<pub-id pub-id-type="other">2-s2.0-84898775157</pub-id>
<pub-id pub-id-type="pmid">24756517</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vijayanathan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>F. T.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>6-OHDA-lesioned adult zebrafish as a useful Parkinson’s disease model for dopaminergic neuroregeneration</article-title>
<source/>
<italic toggle="yes">Neurotoxicity Research</italic>
<year>2017</year>
<volume>32</volume>
<issue>3</issue>
<fpage>496</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-017-9778-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-85023758421</pub-id>
<pub-id pub-id-type="pmid">28707266</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dooley</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zon</surname>
<given-names>L. I.</given-names>
</name>
</person-group>
<article-title>Zebrafish: a model system for the study of human disease</article-title>
<source/>
<italic toggle="yes">Current Opinion in Genetics &amp; Development</italic>
<year>2000</year>
<volume>10</volume>
<issue>3</issue>
<fpage>252</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1016/s0959-437x(00)00074-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034068307</pub-id>
<pub-id pub-id-type="pmid">10826982</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winklhofer</surname>
<given-names>K. F.</given-names>
</name>
<name>
<surname>Haass</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Biochimica et Biophysica Acta</italic>
<year>2010</year>
<volume>1802</volume>
<issue>1</issue>
<fpage>29</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2009.08.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-71849084134</pub-id>
<pub-id pub-id-type="pmid">19733240</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feitosa</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>da Silva Oliveira</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>do Nascimento Cavalcante</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morais Chaves</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Determination of parameters of oxidative stress in vitro models of neurodegenerative diseases—a review</article-title>
<source/>
<italic toggle="yes">Current Clinical Pharmacology</italic>
<year>2018</year>
<volume>13</volume>
<issue>2</issue>
<fpage>100</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.2174/1574884713666180301091612</pub-id>
<pub-id pub-id-type="other">2-s2.0-85055080043</pub-id>
<pub-id pub-id-type="pmid">29493463</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Role of oxidative stress in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Experimental Neurobiology</italic>
<year>2013</year>
<volume>22</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.5607/en.2013.22.1.11</pub-id>
<pub-id pub-id-type="pmid">23585717</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmati-Dinarvand</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>saedi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Valilo</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress and Parkinson's disease: conflict of oxidant-antioxidant systems</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2019</year>
<volume>709</volume>
<fpage>p. 134296</fpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2019.134296</pub-id>
<pub-id pub-id-type="other">2-s2.0-85067309337</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giráldez-Pérez</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Antolín-Vallespín</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muñoz</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Sánchez-Capelo</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Models of <italic>α</italic>-synuclein aggregation in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Acta Neuropathologica Communications</italic>
<year>2014</year>
<volume>2</volume>
<issue>1</issue>
<fpage>p. 176</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-014-0176-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85043616983</pub-id>
<pub-id pub-id-type="pmid">25497491</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinley</surname>
<given-names>E. T.</given-names>
</name>
<name>
<surname>Baranowski</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Blavo</surname>
<given-names>D. O.</given-names>
</name>
<name>
<surname>Cato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Doan</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>A. L.</given-names>
</name>
</person-group>
<article-title>Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons</article-title>
<source/>
<italic toggle="yes">Brain Research. Molecular Brain Research</italic>
<year>2005</year>
<volume>141</volume>
<issue>2</issue>
<fpage>128</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.molbrainres.2005.08.014</pub-id>
<pub-id pub-id-type="other">2-s2.0-27744553546</pub-id>
<pub-id pub-id-type="pmid">16209898</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babu</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Murthy</surname>
<given-names>C. L. N.</given-names>
</name>
<name>
<surname>Kakara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brahmendra Swamy</surname>
<given-names>C. V.</given-names>
</name>
<name>
<surname>Idris</surname>
<given-names>M. M.</given-names>
</name>
</person-group>
<article-title>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease in zebrafish</article-title>
<source/>
<italic toggle="yes">PROTEOMICS</italic>
<year>2016</year>
<volume>16</volume>
<issue>9</issue>
<fpage>1407</fpage>
<lpage>1420</lpage>
<pub-id pub-id-type="doi">10.1002/pmic.201500291</pub-id>
<pub-id pub-id-type="other">2-s2.0-84964797804</pub-id>
<pub-id pub-id-type="pmid">26959078</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S. F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</article-title>
<source/>
<italic toggle="yes">Acta Pharmacologica Sinica</italic>
<year>2016</year>
<volume>22</volume>
<issue>12</issue>
<fpage>1089</fpage>
<lpage>1093</lpage>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbiero</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Santiago</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tonin</surname>
<given-names>F. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PPAR-alpha agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</italic>
<year>2014</year>
<volume>53</volume>
<fpage>35</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.02.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-84896994931</pub-id>
<pub-id pub-id-type="pmid">24593945</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats</article-title>
<source/>
<italic toggle="yes">Neurotoxicology</italic>
<year>2014</year>
<volume>44</volume>
<fpage>71</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2014.05.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-84904261643</pub-id>
<pub-id pub-id-type="pmid">25053526</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mohanakumar</surname>
<given-names>K. P.</given-names>
</name>
</person-group>
<article-title>Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum</article-title>
<source/>
<italic toggle="yes">Journal of Pineal Research</italic>
<year>2004</year>
<volume>36</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1046/j.1600-079x.2003.00096.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-1642440103</pub-id>
<pub-id pub-id-type="pmid">14675127</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Höglinger</surname>
<given-names>G. U.</given-names>
</name>
<name>
<surname>Féger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prigent</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats</article-title>
<source/>
<italic toggle="yes">Journal of Neurochemistry</italic>
<year>2003</year>
<volume>84</volume>
<issue>3</issue>
<fpage>491</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01533.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037314540</pub-id>
<pub-id pub-id-type="pmid">12558969</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherer</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Betarbet</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Greenamyre</surname>
<given-names>J. T.</given-names>
</name>
</person-group>
<article-title>Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and <italic>α</italic>-Synuclein Aggregation</article-title>
<source/>
<italic toggle="yes">Experimental Neurology</italic>
<year>2003</year>
<volume>179</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1006/exnr.2002.8072</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037229425</pub-id>
<pub-id pub-id-type="pmid">12504863</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lapointe</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>St-Hilaire</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martinoli</surname>
<given-names>M. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rotenone induces non‐specific central nervous system and systemic toxicity</article-title>
<source/>
<italic toggle="yes">The FASEB Journal</italic>
<year>2004</year>
<volume>18</volume>
<issue>6</issue>
<fpage>717</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1096/fj.03-0677fje</pub-id>
<pub-id pub-id-type="pmid">14766796</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saravanan</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Sindhu</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Mohanakumar</surname>
<given-names>K. P.</given-names>
</name>
</person-group>
<article-title>Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Brain Research</italic>
<year>2005</year>
<volume>1049</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2005.04.051</pub-id>
<pub-id pub-id-type="other">2-s2.0-23044486663</pub-id>
<pub-id pub-id-type="pmid">15936733</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S. G.</given-names>
</name>
</person-group>
<article-title>alpha-Synuclein redistributed and aggregated in rotenone-induced Parkinson's disease rats</article-title>
<source/>
<italic toggle="yes">Neuroscience Bulletin</italic>
<year>2006</year>
<volume>22</volume>
<issue>5</issue>
<fpage>288</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">17690729</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravenstijn</surname>
<given-names>P. G. M.</given-names>
</name>
<name>
<surname>Merlini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hameetman</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments</article-title>
<source/>
<italic toggle="yes">Journal of Pharmacological and Toxicological Methods</italic>
<year>2008</year>
<volume>57</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.vascn.2007.10.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-40649108829</pub-id>
<pub-id pub-id-type="pmid">18155613</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norazit</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meedeniya</surname>
<given-names>A. C. B.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle</article-title>
<source/>
<italic toggle="yes">Brain Research</italic>
<year>2010</year>
<volume>1360</volume>
<fpage>119</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.08.070</pub-id>
<pub-id pub-id-type="other">2-s2.0-77957953588</pub-id>
<pub-id pub-id-type="pmid">20807515</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chauhan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sandhir</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Neurochemical Research</italic>
<year>2011</year>
<volume>36</volume>
<issue>8</issue>
<fpage>1435</fpage>
<lpage>1443</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-011-0469-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-79961208135</pub-id>
<pub-id pub-id-type="pmid">21484267</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bortolotto</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Cognato</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Christoff</surname>
<given-names>R. R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term exposure to paraquat alters behavioral parameters and dopamine levels in adult zebrafish (Danio rerio)</article-title>
<source/>
<italic toggle="yes">Zebrafish</italic>
<year>2014</year>
<volume>11</volume>
<issue>2</issue>
<fpage>142</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1089/zeb.2013.0923</pub-id>
<pub-id pub-id-type="other">2-s2.0-84898719243</pub-id>
<pub-id pub-id-type="pmid">24568596</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X. H.</given-names>
</name>
<name>
<surname>Souders</surname>
<given-names>C. L.</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Martyniuk</surname>
<given-names>C. J.</given-names>
</name>
</person-group>
<article-title>Paraquat affects mitochondrial bioenergetics, dopamine system expression, and locomotor activity in zebrafish ( _Danio rerio_ )</article-title>
<source/>
<italic toggle="yes">Chemosphere</italic>
<year>2018</year>
<volume>191</volume>
<fpage>106</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.chemosphere.2017.10.032</pub-id>
<pub-id pub-id-type="other">2-s2.0-85031003747</pub-id>
<pub-id pub-id-type="pmid">29031050</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The toxic influence of paraquat on hippocampus of mice: Involvement of oxidative stress</article-title>
<source/>
<italic toggle="yes">NeuroToxicology</italic>
<year>2010</year>
<volume>31</volume>
<issue>3</issue>
<fpage>310</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2010.02.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-77952671501</pub-id>
<pub-id pub-id-type="pmid">20211647</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singhal</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M. P.</given-names>
</name>
</person-group>
<article-title>Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse</article-title>
<source/>
<italic toggle="yes">Journal of Pineal Research</italic>
<year>2010</year>
<pub-id pub-id-type="doi">10.1111/j.1600-079x.2010.00819.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-79951634450</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Sagara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Arroyo</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>α</italic>-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress</article-title>
<source/>
<italic toggle="yes">The American Journal of Pathology</italic>
<year>2000</year>
<volume>157</volume>
<issue>2</issue>
<fpage>401</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1016/s0002-9440(10)64553-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033890821</pub-id>
<pub-id pub-id-type="pmid">10934145</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gitler</surname>
<given-names>A. D.</given-names>
</name>
</person-group>
<article-title>Discovery and characterization of three novel synuclein genes in zebrafish</article-title>
<source/>
<italic toggle="yes">Developmental Dynamics</italic>
<year>2008</year>
<volume>237</volume>
<issue>9</issue>
<fpage>2490</fpage>
<lpage>2495</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.21569</pub-id>
<pub-id pub-id-type="other">2-s2.0-51549090572</pub-id>
<pub-id pub-id-type="pmid">18521955</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabhudesai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Attar</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel “molecular tweezer” inhibitor of <italic>α</italic>-Synuclein neurotoxicity in vitro and in vivo</article-title>
<source/>
<italic toggle="yes">Neurotherapeutics</italic>
<year>2012</year>
<volume>9</volume>
<issue>2</issue>
<fpage>464</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-012-0105-1</pub-id>
<pub-id pub-id-type="other">2-s2.0-84859708060</pub-id>
<pub-id pub-id-type="pmid">22373667</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosco</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate <italic>α</italic>-synuclein fibrilization</article-title>
<source/>
<italic toggle="yes">Nature Chemical Biology</italic>
<year>2006</year>
<volume>2</volume>
<issue>5</issue>
<fpage>249</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio782</pub-id>
<pub-id pub-id-type="other">2-s2.0-33646451063</pub-id>
<pub-id pub-id-type="pmid">16565714</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Youdim</surname>
<given-names>M. B. H.</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>MPTP-induced Parkinsonian syndrome</article-title>
<source/>
<italic toggle="yes">Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th ed.</italic>
<year>1999</year>
<publisher-loc>Philadelphia</publisher-loc>
<publisher-name>Lippincott-Raven</publisher-name>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betarbet</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sherer</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Greenamyre</surname>
<given-names>J. T.</given-names>
</name>
</person-group>
<article-title>Animal models of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">BioEssays</italic>
<year>2002</year>
<volume>24</volume>
<issue>4</issue>
<fpage>308</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1002/bies.10067</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036010592</pub-id>
<pub-id pub-id-type="pmid">11948617</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nellore</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>P</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Paraquat exposure induces behavioral deficits in larval zebrafish during the window of dopamine neurogenesis</article-title>
<source/>
<italic toggle="yes">Toxicology Reports</italic>
<year>2015</year>
<volume>2</volume>
<fpage>950</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxrep.2015.06.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84934325669</pub-id>
<pub-id pub-id-type="pmid">28962434</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>C.-W.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Z.-H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.-Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae</article-title>
<source/>
<italic toggle="yes">Zebrafish</italic>
<year>2014</year>
<volume>11</volume>
<issue>3</issue>
<fpage>227</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1089/zeb.2013.0950</pub-id>
<pub-id pub-id-type="other">2-s2.0-84902344447</pub-id>
<pub-id pub-id-type="pmid">24720843</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cronin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grealy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2017</year>
<volume>367</volume>
<fpage>34</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.10.018</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032937009</pub-id>
<pub-id pub-id-type="pmid">29079063</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benvenutti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marcon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>C. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>N-acetylcysteine protects against motor, optomotor and morphological deficits induced by 6-OHDA in zebrafish larvae</article-title>
<source/>
<italic toggle="yes">PeerJ</italic>
<year>2018</year>
<volume>6</volume>
<fpage>p. e4957</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.4957</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048121852</pub-id>
<pub-id pub-id-type="pmid">29868300</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langston</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>The MPTP story</article-title>
<source/>
<italic toggle="yes">Journal of Parkinson's Disease</italic>
<year>2017</year>
<volume>7</volume>
<issue>s1</issue>
<fpage>S11</fpage>
<lpage>S19</lpage>
<pub-id pub-id-type="doi">10.3233/jpd-179006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85026491508</pub-id>
<pub-id pub-id-type="pmid">28282815</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Plotegher</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boassa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bubacco</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Impaired dopamine metabolism in Parkinson’s disease pathogenesis</article-title>
<source/>
<italic toggle="yes">Molecular Neurodegeneration</italic>
<year>2019</year>
<volume>14</volume>
<issue>1</issue>
<fpage>p. 35</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-019-0332-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85071751307</pub-id>
<pub-id pub-id-type="pmid">31488222</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farooqui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Farooqui</surname>
<given-names>A. A.</given-names>
</name>
</person-group>
<article-title>Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson's Disease</article-title>
<source/>
<italic toggle="yes">Parkinson's Disease</italic>
<year>2011</year>
<volume>2011</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.4061/2011/247467</pub-id>
<pub-id pub-id-type="other">2-s2.0-79953272320</pub-id>
<pub-id pub-id-type="pmid">21403820</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Oxidative stress, mitochondrial respiration, and Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Annals of the New York Academy of Sciences</italic>
<year>2000</year>
<volume>899</volume>
<issue>1</issue>
<fpage>112</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06180.x</pub-id>
<pub-id pub-id-type="pmid">10863533</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Calvani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rizzarelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Giuffrida Stella</surname>
<given-names>A. M.</given-names>
</name>
</person-group>
<article-title>Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity</article-title>
<source/>
<italic toggle="yes">Nature Reviews. Neuroscience</italic>
<year>2007</year>
<volume>8</volume>
<issue>10</issue>
<fpage>766</fpage>
<lpage>775</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2214</pub-id>
<pub-id pub-id-type="other">2-s2.0-34648836983</pub-id>
<pub-id pub-id-type="pmid">17882254</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.-S.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>C. M.</given-names>
</name>
</person-group>
<article-title>Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives</article-title>
<source/>
<italic toggle="yes">Current Neurology and Neuroscience Reports</italic>
<year>2018</year>
<volume>18</volume>
<issue>5</issue>
<fpage>p. 21</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-018-0829-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-85044968003</pub-id>
<pub-id pub-id-type="pmid">29616350</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shams</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rihel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Gerlai</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The zebrafish as a promising tool for modeling human brain disorders: a review based upon an IBNS symposium</article-title>
<source/>
<italic toggle="yes">Neuroscience and Biobehavioral Reviews</italic>
<year>2018</year>
<volume>85</volume>
<fpage>176</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.09.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028946117</pub-id>
<pub-id pub-id-type="pmid">28887224</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meredith</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Rademacher</surname>
<given-names>D. J.</given-names>
</name>
</person-group>
<article-title>MPTP mouse models of Parkinson’s disease: an update</article-title>
<source/>
<italic toggle="yes">Journal of Parkinson's Disease</italic>
<year>2011</year>
<volume>1</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.3233/JPD-2011-11023</pub-id>
<pub-id pub-id-type="other">2-s2.0-79958214912</pub-id>
<pub-id pub-id-type="pmid">23275799</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schwarting</surname>
<given-names>R. K. W.</given-names>
</name>
<name>
<surname>Huston</surname>
<given-names>J. P.</given-names>
</name>
</person-group>
<article-title>Behavioral phenotyping of the MPTP mouse model of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Behavioural Brain Research</italic>
<year>2001</year>
<volume>125</volume>
<issue>1–2</issue>
<fpage>109</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1016/s0166-4328(01)00309-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035829368</pub-id>
<pub-id pub-id-type="pmid">11682102</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaz</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Outeiro</surname>
<given-names>T. F.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>J. J.</given-names>
</name>
</person-group>
<article-title>Zebrafish as an animal model for drug discovery in Parkinson’s disease and other movement disorders: a systematic review</article-title>
<source/>
<italic toggle="yes">Frontiers in Neurology</italic>
<year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fneur.2018.00347</pub-id>
<pub-id pub-id-type="other">2-s2.0-85047880162</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson-Lewis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Blesa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Animal models of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Parkinsonism &amp; Related Disorders</italic>
<year>2012</year>
<volume>18</volume>
<fpage>S183</fpage>
<lpage>S185</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(11)70057-8</pub-id>
<pub-id pub-id-type="pmid">22166429</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchhoff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mork</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brennum</surname>
<given-names>L. T.</given-names>
</name>
<name>
<surname>Sager</surname>
<given-names>T. N.</given-names>
</name>
</person-group>
<article-title>Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice</article-title>
<source/>
<italic toggle="yes">NeuroReport</italic>
<year>2009</year>
<volume>20</volume>
<issue>5</issue>
<fpage>482</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1097/wnr.0b013e32832984d6</pub-id>
<pub-id pub-id-type="other">2-s2.0-63849206689</pub-id>
<pub-id pub-id-type="pmid">19262413</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mingazov</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Khakimova</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Kozina</surname>
<given-names>E. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MPTP mouse model of preclinical and clinical Parkinson’s disease as an instrument for translational medicine</article-title>
<source/>
<italic toggle="yes">Molecular Neurobiology</italic>
<year>2018</year>
<volume>55</volume>
<issue>4</issue>
<fpage>2991</fpage>
<lpage>3006</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-017-0559-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018285778</pub-id>
<pub-id pub-id-type="pmid">28456940</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Korzh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Strahle</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP</article-title>
<source/>
<italic toggle="yes">The European Journal of Neuroscience</italic>
<year>2005</year>
<volume>21</volume>
<issue>6</issue>
<fpage>1758</fpage>
<lpage>1762</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.03988.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-18444390582</pub-id>
<pub-id pub-id-type="pmid">15845104</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabashi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brustein</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Champagne</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Drapeau</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Zebrafish models for the functional genomics of neurogenetic disorders</article-title>
<source/>
<italic toggle="yes">Biochimica et Biophysica Acta</italic>
<year>2011</year>
<volume>1812</volume>
<issue>3</issue>
<fpage>335</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2010.09.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-78751704366</pub-id>
<pub-id pub-id-type="pmid">20887784</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simola</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>A. R.</given-names>
</name>
</person-group>
<article-title>The 6-hydroxydopamine model of Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Neurotoxicity Research</italic>
<year>2007</year>
<volume>11</volume>
<issue>3–4</issue>
<fpage>151</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1007/bf03033565</pub-id>
<pub-id pub-id-type="other">2-s2.0-34548458484</pub-id>
<pub-id pub-id-type="pmid">17449457</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schober</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP</article-title>
<source/>
<italic toggle="yes">Cell and Tissue Research</italic>
<year>2004</year>
<volume>318</volume>
<issue>1</issue>
<fpage>215</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1007/s00441-004-0938-y</pub-id>
<pub-id pub-id-type="other">2-s2.0-5544229693</pub-id>
<pub-id pub-id-type="pmid">15503155</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glinka</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Youdim</surname>
<given-names>M. B. H.</given-names>
</name>
</person-group>
<article-title>Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>1995</year>
<volume>292</volume>
<issue>3–4</issue>
<fpage>329</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1016/0926-6917(95)90040-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-0028918841</pub-id>
<pub-id pub-id-type="pmid">7796873</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deumens</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Blokland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Prickaerts</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway</article-title>
<source/>
<italic toggle="yes">Experimental Neurology</italic>
<year>2002</year>
<volume>175</volume>
<issue>2</issue>
<fpage>303</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1006/exnr.2002.7891</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036283426</pub-id>
<pub-id pub-id-type="pmid">12061862</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Jordán</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Solesio</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Galindo</surname>
<given-names>M. F.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Hayat</surname>
<given-names>M. A. B. T.-A. C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial alterations and mitophagy in response to 6-hydroxydopamine</article-title>
<source/>
<italic toggle="yes">Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging</italic>
<year>2014</year>
<publisher-loc>Amsterdam</publisher-loc>
<publisher-name>Academic Press</publisher-name>
<fpage>201</fpage>
<lpage>209</lpage>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Ton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Neurotoxicity assessment using zebrafish</article-title>
<source/>
<italic toggle="yes">Journal of Pharmacological and Toxicological Methods</italic>
<year>2007</year>
<volume>55</volume>
<issue>1</issue>
<fpage>103</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1016/j.vascn.2006.04.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-33846027436</pub-id>
<pub-id pub-id-type="pmid">16769228</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bensadoun</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Mirochnitchenko</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Inouye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aebischer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zurn</surname>
<given-names>A. D.</given-names>
</name>
</person-group>
<article-title>Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice</article-title>
<source/>
<italic toggle="yes">The European Journal of Neuroscience</italic>
<year>1998</year>
<volume>10</volume>
<issue>10</issue>
<fpage>3231</fpage>
<lpage>3236</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.1998.00345.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0032445774</pub-id>
<pub-id pub-id-type="pmid">9786216</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robea</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Strungaru</surname>
<given-names>S.-A.</given-names>
</name>
<name>
<surname>Lenzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nicoara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciobica</surname>
</name>
</person-group>
<article-title>The importance of rotenone in generating neurological and psychiatric features in zebrafish-relevance for a Parkinson’s disease model</article-title>
<source/>
<italic toggle="yes">Academy of Romanian Scientists</italic>
<year>2018</year>
<volume>7</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>67</lpage>
</element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models</article-title>
<source/>
<italic toggle="yes">Critical Reviews in Toxicology</italic>
<year>2012</year>
<volume>42</volume>
<issue>7</issue>
<fpage>613</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.3109/10408444.2012.680431</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863666597</pub-id>
<pub-id pub-id-type="pmid">22574684</pub-id>
</element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heikkila</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Nicklas</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Vyas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>R. C.</given-names>
</name>
</person-group>
<article-title>Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>1985</year>
<volume>62</volume>
<issue>3</issue>
<fpage>389</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(85)90580-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-0022403289</pub-id>
<pub-id pub-id-type="pmid">3912685</pub-id>
</element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ragheb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lawler</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production</article-title>
<source/>
<italic toggle="yes">The Journal of Biological Chemistry</italic>
<year>2003</year>
<volume>278</volume>
<issue>10</issue>
<fpage>8516</fpage>
<lpage>8525</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.m210432200</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037424245</pub-id>
<pub-id pub-id-type="pmid">12496265</pub-id>
</element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>ALAM</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>SCHMIDT</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Physiology &amp; Behavior</italic>
<year>2004</year>
<volume>83</volume>
<issue>3</issue>
<fpage>395</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2004.08.010</pub-id>
<pub-id pub-id-type="other">2-s2.0-9744274529</pub-id>
<pub-id pub-id-type="pmid">15581661</pub-id>
</element-citation>
</ref>
<ref id="B110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease-like motor and non-motor symptoms in rotenone-treated zebrafish</article-title>
<source/>
<italic toggle="yes">Neurotoxicology</italic>
<year>2017</year>
<volume>58</volume>
<fpage>103</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2016.11.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85002410472</pub-id>
<pub-id pub-id-type="pmid">27866991</pub-id>
</element-citation>
</ref>
<ref id="B111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Keow</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Ekker</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Rotenone Neurotoxicity Causes Dopamine Neuron Loss in Zebrafish</article-title>
<source/>
<italic toggle="yes">University of Ottawa Journal of Medicine</italic>
<year>2015</year>
<volume>5</volume>
<issue>2</issue>
<fpage>16</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.18192/uojm.v5i2.1413</pub-id>
</element-citation>
</ref>
<ref id="B112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melo</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grisolia</surname>
<given-names>C. K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Short-term exposure to low doses of rotenone induces developmental, biochemical, behavioral, and histological changes in fish</article-title>
<source/>
<italic toggle="yes">Environmental Science and Pollution Research International</italic>
<year>2015</year>
<volume>22</volume>
<issue>18</issue>
<fpage>13926</fpage>
<lpage>13938</lpage>
<pub-id pub-id-type="doi">10.1007/s11356-015-4596-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-84941183935</pub-id>
<pub-id pub-id-type="pmid">25948382</pub-id>
</element-citation>
</ref>
<ref id="B113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cocheme</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M. P.</given-names>
</name>
</person-group>
<article-title>Complex I is the major site of mitochondrial superoxide production by paraquat</article-title>
<source/>
<italic toggle="yes">The Journal of Biological Chemistry</italic>
<year>2008</year>
<volume>283</volume>
<issue>4</issue>
<fpage>1786</fpage>
<lpage>1798</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M708597200</pub-id>
<pub-id pub-id-type="other">2-s2.0-38349105900</pub-id>
<pub-id pub-id-type="pmid">18039652</pub-id>
</element-citation>
</ref>
<ref id="B114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adibhatla</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Hatcher</surname>
<given-names>J. F.</given-names>
</name>
</person-group>
<article-title>Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities</article-title>
<source/>
<italic toggle="yes">Antioxidants &amp; Redox Signaling</italic>
<year>2010</year>
<volume>12</volume>
<issue>1</issue>
<fpage>125</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2009.2668</pub-id>
<pub-id pub-id-type="other">2-s2.0-71549144988</pub-id>
<pub-id pub-id-type="pmid">19624272</pub-id>
</element-citation>
</ref>
<ref id="B115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shichiri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of lipid peroxidation in neurological disorders</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Biochemistry and Nutrition</italic>
<year>2014</year>
<volume>54</volume>
<issue>3</issue>
<fpage>151</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.3164/jcbn.14-10</pub-id>
<pub-id pub-id-type="other">2-s2.0-84900439903</pub-id>
<pub-id pub-id-type="pmid">24895477</pub-id>
</element-citation>
</ref>
<ref id="B116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunes</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Braga</surname>
<given-names>M. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic treatment with Paraquat induces brain injury, changes in antioxidant defenses system, and modulates behavioral functions in zebrafish</article-title>
<source/>
<italic toggle="yes">Molecular Neurobiology</italic>
<year>2017</year>
<volume>54</volume>
<issue>6</issue>
<fpage>3925</fpage>
<lpage>3934</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-9919-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84970024585</pub-id>
<pub-id pub-id-type="pmid">27229491</pub-id>
</element-citation>
</ref>
<ref id="B117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poewe</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zijlmans</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Burkhard</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Vingerhoets</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Levodopa in the treatment of Parkinson&amp;rsquo;s disease: an old drug still going strong</article-title>
<source/>
<italic toggle="yes">Clinical Interventions in Aging</italic>
<year>2010</year>
<volume>5</volume>
<fpage>229</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.2147/cia.s6456</pub-id>
<pub-id pub-id-type="pmid">20852670</pub-id>
</element-citation>
</ref>
<ref id="B118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhall</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kreitzman</surname>
<given-names>D. L.</given-names>
</name>
</person-group>
<article-title>Advances in levodopa therapy for Parkinson disease</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2016</year>
<volume>86</volume>
<issue>14 Supplement 1</issue>
<fpage>S13</fpage>
<lpage>S24</lpage>
<pub-id pub-id-type="doi">10.1212/wnl.0000000000002510</pub-id>
<pub-id pub-id-type="other">2-s2.0-84982190147</pub-id>
<pub-id pub-id-type="pmid">27044646</pub-id>
</element-citation>
</ref>
<ref id="B119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Levodopa and Dopamine Agonists in the Treatment of Parkinson’s Disease: Advantages and Disadvantages</article-title>
<source/>
<italic toggle="yes">European Neurology</italic>
<year>2004</year>
<volume>34</volume>
<issue>3</issue>
<fpage>20</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1159/000119538</pub-id>
<pub-id pub-id-type="other">2-s2.0-0027999079</pub-id>
</element-citation>
</ref>
<ref id="B120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riederer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Laux</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>MAO-inhibitors in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Experimental Neurobiology</italic>
<year>2011</year>
<volume>20</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.5607/en.2011.20.1.1</pub-id>
<pub-id pub-id-type="pmid">22110357</pub-id>
</element-citation>
</ref>
<ref id="B121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dezsi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vecsei</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Monoamine oxidase B inhibitors in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">CNS &amp; Neurological Disorders Drug Targets</italic>
<year>2017</year>
<volume>16</volume>
<issue>4</issue>
<fpage>425</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="doi">10.2174/1871527316666170124165222</pub-id>
<pub-id pub-id-type="other">2-s2.0-85027250456</pub-id>
<pub-id pub-id-type="pmid">28124620</pub-id>
</element-citation>
</ref>
<ref id="B122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>Deprenyl, a therapeutic agent for Parkinson’s disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation</article-title>
<source/>
<italic toggle="yes">Journal of Toxicology and Environmental Health. Part A</italic>
<year>2004</year>
<volume>67</volume>
<issue>23–24</issue>
<fpage>2013</fpage>
<lpage>2024</lpage>
<pub-id pub-id-type="doi">10.1080/15287390490514732</pub-id>
<pub-id pub-id-type="other">2-s2.0-8444252969</pub-id>
<pub-id pub-id-type="pmid">15513899</pub-id>
</element-citation>
</ref>
<ref id="B123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prema</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Janakiraman</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Manivasagam</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Justin Thenmozhi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neuroprotective effect of lycopene against MPTP induced experimental Parkinson's disease in mice</article-title>
<source/>
<italic toggle="yes">Neuroscience Letters</italic>
<year>2015</year>
<volume>599</volume>
<fpage>12</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.05.024</pub-id>
<pub-id pub-id-type="other">2-s2.0-84930006839</pub-id>
<pub-id pub-id-type="pmid">25980996</pub-id>
</element-citation>
</ref>
<ref id="B124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodwin</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J. L.</given-names>
</name>
</person-group>
<article-title>The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis</article-title>
<source/>
<italic toggle="yes">Movement Disorders</italic>
<year>2008</year>
<volume>23</volume>
<issue>5</issue>
<fpage>631</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21922</pub-id>
<pub-id pub-id-type="other">2-s2.0-44449153709</pub-id>
<pub-id pub-id-type="pmid">18181210</pub-id>
</element-citation>
</ref>
<ref id="B125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Timofte</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ciobica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Honceriu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trofin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ciobica</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cojocaru</surname>
</name>
</person-group>
<article-title>A mini-review on the effects of exercising and obsesity in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Ann. Ser. Biol. Sci.</italic>
<year>2017</year>
<volume>6</volume>
<issue>1</issue>
<fpage>100</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="B126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cano-de-la-Cuerda</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pérez-de-Heredia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miangolarra-Page</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Muñoz-Hellín</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fernández-de-las-Peñas</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Is there muscular weakness in Parkinson's disease?</article-title>
<source/>
<italic toggle="yes">American Journal of Physical Medicine &amp; Rehabilitation</italic>
<year>2010</year>
<volume>89</volume>
<issue>1</issue>
<fpage>70</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1097/phm.0b013e3181a9ed9b</pub-id>
<pub-id pub-id-type="other">2-s2.0-73949086501</pub-id>
<pub-id pub-id-type="pmid">19487924</pub-id>
</element-citation>
</ref>
<ref id="B127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Volpe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clifford</surname>
<given-names>A. M.</given-names>
</name>
</person-group>
<article-title>Aquatic exercise therapy for people with Parkinson disease: a randomized controlled trial</article-title>
<source/>
<italic toggle="yes">Archives of Physical Medicine and Rehabilitation</italic>
<year>2017</year>
<volume>98</volume>
<issue>4</issue>
<fpage>631</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="doi">10.1016/j.apmr.2016.12.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012909158</pub-id>
<pub-id pub-id-type="pmid">28088380</pub-id>
</element-citation>
</ref>
<ref id="B128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porkka-Heiskanen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zitting</surname>
<given-names>K.-M.</given-names>
</name>
<name>
<surname>Wigren</surname>
<given-names>H.-K.</given-names>
</name>
</person-group>
<article-title>Sleep, its regulation and possible mechanisms of sleep disturbances</article-title>
<source/>
<italic toggle="yes">Acta Physiologica (Oxford, England)</italic>
<year>2013</year>
<volume>208</volume>
<issue>4</issue>
<fpage>311</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1111/apha.12134</pub-id>
<pub-id pub-id-type="other">2-s2.0-84880395594</pub-id>
</element-citation>
</ref>
<ref id="B129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bienfait</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Sleep disturbances in Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Movement Disorders</italic>
<year>2010</year>
<volume>25</volume>
<issue>S1</issue>
<supplement>Suppl 1</supplement>
<fpage>S117</fpage>
<lpage>S122</lpage>
<pub-id pub-id-type="doi">10.1002/mds.22788</pub-id>
<pub-id pub-id-type="other">2-s2.0-77953442615</pub-id>
<pub-id pub-id-type="pmid">20187236</pub-id>
</element-citation>
</ref>
<ref id="B130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvaraj</surname>
<given-names>V. K.</given-names>
</name>
</person-group>
<article-title>Sleep Dysfunction in Parkinson's Disease</article-title>
<source/>
<italic toggle="yes">JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH</italic>
<year>2016</year>
<pub-id pub-id-type="doi">10.7860/jcdr/2016/16446.7208</pub-id>
<pub-id pub-id-type="other">2-s2.0-84957110685</pub-id>
</element-citation>
</ref>
<ref id="B131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagnon</surname>
<given-names>J.-F.</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Latreille</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Montplaisir</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Neurobiology of sleep disturbances in neurodegenerative disorders</article-title>
<source/>
<italic toggle="yes">Current Pharmaceutical Design</italic>
<year>2008</year>
<volume>14</volume>
<issue>32</issue>
<fpage>3430</fpage>
<lpage>3445</lpage>
<pub-id pub-id-type="doi">10.2174/138161208786549353</pub-id>
<pub-id pub-id-type="other">2-s2.0-58949098040</pub-id>
<pub-id pub-id-type="pmid">19075719</pub-id>
</element-citation>
</ref>
<ref id="B132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnen</surname>
<given-names>N. I.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M. T. M.</given-names>
</name>
</person-group>
<article-title>Sleep disturbance as potential risk and progression factor for Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Journal of Parkinson's Disease</italic>
<year>2019</year>
<volume>9</volume>
<issue>3</issue>
<fpage>603</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.3233/JPD-191627</pub-id>
<pub-id pub-id-type="other">2-s2.0-85070241533</pub-id>
<pub-id pub-id-type="pmid">31227656</pub-id>
</element-citation>
</ref>
<ref id="B133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loddo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Calandra-Buonaura</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sambati</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice</article-title>
<source/>
<italic toggle="yes">Frontiers in Neurology</italic>
<year>2017</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.3389/fneur.2017.00042</pub-id>
<pub-id pub-id-type="other">2-s2.0-85014244317</pub-id>
</element-citation>
</ref>
<ref id="B134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gjerstad</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Wentzel-Larsen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>J. P.</given-names>
</name>
</person-group>
<article-title>Insomnia in Parkinson’s disease: frequency and progression over time</article-title>
<source/>
<italic toggle="yes">Journal of Neurology, Neurosurgery, and Psychiatry</italic>
<year>2006</year>
<volume>78</volume>
<issue>5</issue>
<fpage>476</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2006.100370</pub-id>
<pub-id pub-id-type="other">2-s2.0-34247192003</pub-id>
<pub-id pub-id-type="pmid">17098844</pub-id>
</element-citation>
</ref>
<ref id="B135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>R.-l.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C.-j.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P.-p.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Clinical variations in Parkinson's disease patients with or without REM sleep behaviour disorder: a meta-analysis</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1038/srep40779</pub-id>
<pub-id pub-id-type="other">2-s2.0-85009913081</pub-id>
</element-citation>
</ref>
<ref id="B136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Jaimchariyatam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Budur</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Rapid eye movement sleep behavior disorder: a review of the literature and update on current concepts</article-title>
<source/>
<italic toggle="yes">Chest</italic>
<year>2017</year>
<volume>152</volume>
<issue>3</issue>
<fpage>650</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1016/j.chest.2017.03.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028969269</pub-id>
<pub-id pub-id-type="pmid">28322726</pub-id>
</element-citation>
</ref>
<ref id="B137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adler</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Hentz</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Shill</surname>
<given-names>H. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probable RBD is increased in Parkinson’s disease but not in essential tremor or restless legs syndrome</article-title>
<source/>
<italic toggle="yes">Parkinsonism &amp; Related Disorders</italic>
<year>2011</year>
<volume>17</volume>
<issue>6</issue>
<fpage>456</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2011.03.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-79959344260</pub-id>
<pub-id pub-id-type="pmid">21482171</pub-id>
</element-citation>
</ref>
<ref id="B138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y. E.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>B. S.</given-names>
</name>
</person-group>
<article-title>Clinical implication of REM sleep behavior disorder in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">Journal of Parkinson's Disease</italic>
<year>2014</year>
<volume>4</volume>
<issue>2</issue>
<fpage>237</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.3233/JPD-130293</pub-id>
<pub-id pub-id-type="other">2-s2.0-84901840107</pub-id>
<pub-id pub-id-type="pmid">24613864</pub-id>
</element-citation>
</ref>
<ref id="B139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">BMC Neurology</italic>
<year>2017</year>
<volume>17</volume>
<issue>1</issue>
<fpage>p. 23</fpage>
<pub-id pub-id-type="doi">10.1186/s12883-017-0795-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-85011534460</pub-id>
<pub-id pub-id-type="pmid">28160778</pub-id>
</element-citation>
</ref>
<ref id="B140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghazi Sherbaf</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rostam Abadi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mojtahed Zadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ashraf-Ganjouei</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanjari Moghaddam</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aarabi</surname>
<given-names>M. H.</given-names>
</name>
</person-group>
<article-title>Microstructural changes in patients with Parkinson’s disease comorbid with REM sleep behaviour disorder and depressive symptoms</article-title>
<source/>
<italic toggle="yes">Frontiers in Neurology</italic>
<year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fneur.2018.00441</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049119551</pub-id>
</element-citation>
</ref>
<ref id="B141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Happe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trenkwalder</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Movement disorders in sleep: Parkinson’s disease and restless legs syndrome</article-title>
<source/>
<italic toggle="yes">Biomedizinische Technik. Biomedical Engineering</italic>
<year>2003</year>
<volume>48</volume>
<issue>3</issue>
<fpage>62</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1515/bmte.2003.48.3.62</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037346693</pub-id>
<pub-id pub-id-type="pmid">12701336</pub-id>
</element-citation>
</ref>
<ref id="B142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piao</surname>
<given-names>Y.-S.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Restless legs syndrome in Parkinson disease: clinical characteristics, abnormal iron metabolism and altered neurotransmitters</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 10547</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-10593-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028932714</pub-id>
<pub-id pub-id-type="pmid">28874701</pub-id>
</element-citation>
</ref>
<ref id="B143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wetter</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Collado-Seidel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pollmacher</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yassouridis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trenkwalder</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Sleep and periodic leg movement patterns in drug-free patients with Parkinson’s disease and multiple system atrophy</article-title>
<source/>
<italic toggle="yes">Sleep</italic>
<year>2000</year>
<volume>23</volume>
<issue>3</issue>
<fpage>361</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="pmid">10811380</pub-id>
</element-citation>
</ref>
<ref id="B144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ondo</surname>
<given-names>W. G.</given-names>
</name>
<name>
<surname>Vuong</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Exploring the relationship between Parkinson disease and restless legs syndrome</article-title>
<source/>
<italic toggle="yes">Archives of Neurology</italic>
<year>2002</year>
<volume>59</volume>
<issue>3</issue>
<fpage>421</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.59.3.421</pub-id>
<pub-id pub-id-type="other">2-s2.0-0036186469</pub-id>
<pub-id pub-id-type="pmid">11890847</pub-id>
</element-citation>
</ref>
<ref id="B145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peeraully</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>E.-K.</given-names>
</name>
</person-group>
<article-title>Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence</article-title>
<source/>
<italic toggle="yes">Translational Neurodegeneration</italic>
<year>2012</year>
<volume>1</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1186/2047-9158-1-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-84879499870</pub-id>
<pub-id pub-id-type="pmid">23211049</pub-id>
</element-citation>
</ref>
<ref id="B146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lungato</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>V. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep deprivation alters gene expression and antioxidant enzyme activity in mice splenocytes</article-title>
<source/>
<italic toggle="yes">Scandinavian Journal of Immunology</italic>
<year>2013</year>
<volume>77</volume>
<issue>3</issue>
<fpage>195</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1111/sji.12029</pub-id>
<pub-id pub-id-type="other">2-s2.0-84875607168</pub-id>
<pub-id pub-id-type="pmid">23360182</pub-id>
</element-citation>
</ref>
<ref id="B147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villafuerte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Miguel-Puga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murillo Rodríguez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Manjarrez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arias-Carrión</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Sleep deprivation and oxidative stress in animal models: a systematic review</article-title>
<source/>
<italic toggle="yes">Oxidative Medicine and Cellular Longevity</italic>
<year>2015</year>
<volume>2015</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1155/2015/234952</pub-id>
<pub-id pub-id-type="other">2-s2.0-84928501071</pub-id>
<pub-id pub-id-type="pmid">25945148</pub-id>
</element-citation>
</ref>
<ref id="B148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Holger</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Craddock</surname>
<given-names>T. J. A.</given-names>
</name>
<name>
<surname>Tartar</surname>
<given-names>J. L.</given-names>
</name>
</person-group>
<article-title>Short-term sleep deprivation leads to decreased systemic redox metabolites and altered epigenetic status</article-title>
<source/>
<italic toggle="yes">PLOS ONE</italic>
<year>2017</year>
<volume>12</volume>
<issue>7</issue>
<fpage>p. e0181978</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0181978</pub-id>
<pub-id pub-id-type="other">2-s2.0-85025126965</pub-id>
<pub-id pub-id-type="pmid">28738082</pub-id>
</element-citation>
</ref>
<ref id="B149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenwood</surname>
<given-names>B. N.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Opp</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Fleshner</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Repeated exposure to conditioned fear stress increases anxiety and delays sleep recovery following exposure to an acute traumatic stressor</article-title>
<source/>
<italic toggle="yes">Frontiers in Psychiatry</italic>
<year>2014</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00146</pub-id>
<pub-id pub-id-type="other">2-s2.0-84909972009</pub-id>
</element-citation>
</ref>
<ref id="B150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filograna</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Beltramini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bubacco</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bisaglia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anti-oxidants in Parkinson’s disease therapy: a critical point of view</article-title>
<source/>
<italic toggle="yes">Current Neuropharmacology</italic>
<year>2016</year>
<volume>14</volume>
<issue>3</issue>
<fpage>260</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.2174/1570159x13666151030102718</pub-id>
<pub-id pub-id-type="other">2-s2.0-84961762846</pub-id>
<pub-id pub-id-type="pmid">26517052</pub-id>
</element-citation>
</ref>
<ref id="B151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaminska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lafontaine</surname>
<given-names>A.-L.</given-names>
</name>
<name>
<surname>Kimoff</surname>
<given-names>R. J.</given-names>
</name>
</person-group>
<article-title>The interaction between obstructive sleep apnea and Parkinson’s disease: possible mechanisms and implications for cognitive function</article-title>
<source/>
<italic toggle="yes">Parkinson's Disease</italic>
<year>2015</year>
<volume>2015</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1155/2015/849472</pub-id>
<pub-id pub-id-type="other">2-s2.0-84945408273</pub-id>
<pub-id pub-id-type="pmid">26509097</pub-id>
</element-citation>
</ref>
<ref id="B152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Appleton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Atlantis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Magnesium intake and sleep disorder symptoms: findings from the Jiangsu Nutrition Study of Chinese adults at five-year follow-up</article-title>
<source/>
<italic toggle="yes">Nutrients</italic>
<year>2018</year>
<volume>10</volume>
<issue>10</issue>
<fpage>p. 1354</fpage>
<pub-id pub-id-type="doi">10.3390/nu10101354</pub-id>
<pub-id pub-id-type="other">2-s2.0-85053817785</pub-id>
<pub-id pub-id-type="pmid">30248967</pub-id>
</element-citation>
</ref>
<ref id="B153">
<label>153</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Oyanagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Magnesium in Parkinson’s disease: an update in clinical and basic aspects</article-title>
<source/>
<italic toggle="yes">Magnesium in the Central Nervous System</italic>
<year>2011</year>
<publisher-name>University of Adelaide Press</publisher-name>
</element-citation>
</ref>
<ref id="B154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sturgeon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cornell</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>SLC41A1 and TRPM7 in magnesium homeostasis and genetic risk for Parkinson’s disease</article-title>
<source/>
<italic toggle="yes">J. Neurol. neuromedicine</italic>
<year>2016</year>
<volume>1</volume>
<issue>9</issue>
<fpage>23</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">31187092</pub-id>
</element-citation>
</ref>
<ref id="B155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.-F.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.-J.</given-names>
</name>
</person-group>
<article-title>Elevated circulating magnesium levels in patients with Parkinson’s disease: a meta-analysis</article-title>
<source/>
<italic toggle="yes">Neuropsychiatric Disease and Treatment</italic>
<year>2018</year>
<volume>Volume 14</volume>
<fpage>3159</fpage>
<lpage>3168</lpage>
<pub-id pub-id-type="doi">10.2147/ndt.s186209</pub-id>
<pub-id pub-id-type="other">2-s2.0-85057570791</pub-id>
<pub-id pub-id-type="pmid">30510425</pub-id>
</element-citation>
</ref>
<ref id="B156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan-Or</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Noreau</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease genetic loci in rapid eye movement sleep behavior disorder</article-title>
<source/>
<italic toggle="yes">Journal of Molecular Neuroscience</italic>
<year>2015</year>
<volume>56</volume>
<issue>3</issue>
<fpage>617</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-015-0569-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-84931569448</pub-id>
<pub-id pub-id-type="pmid">25929833</pub-id>
</element-citation>
</ref>
<ref id="B157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nedergaard</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Changes in the composition of brain interstitial ions control the sleep-wake cycle</article-title>
<source/>
<italic toggle="yes">Science</italic>
<year>2016</year>
<volume>352</volume>
<issue>6285</issue>
<fpage>550</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1126/science.aad4821</pub-id>
<pub-id pub-id-type="other">2-s2.0-84968792150</pub-id>
<pub-id pub-id-type="pmid">27126038</pub-id>
</element-citation>
</ref>
<ref id="B158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anichtchik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Diekmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Roach</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rubinsztein</surname>
<given-names>D. C.</given-names>
</name>
</person-group>
<article-title>Loss of PINK1 function affects development and results in neurodegeneration in zebrafish</article-title>
<source/>
<italic toggle="yes">The Journal of Neuroscience</italic>
<year>2008</year>
<volume>28</volume>
<issue>33</issue>
<fpage>8199</fpage>
<lpage>8207</lpage>
<pub-id pub-id-type="doi">10.1523/jneurosci.0979-08.2008</pub-id>
<pub-id pub-id-type="other">2-s2.0-51149105923</pub-id>
<pub-id pub-id-type="pmid">18701682</pub-id>
</element-citation>
</ref>
<ref id="B159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gautier</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Kitada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic>
<year>2008</year>
<volume>105</volume>
<issue>32</issue>
<fpage>11364</fpage>
<lpage>11369</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0802076105</pub-id>
<pub-id pub-id-type="other">2-s2.0-49649097747</pub-id>
<pub-id pub-id-type="pmid">18687901</pub-id>
</element-citation>
</ref>
<ref id="B160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priyadarshini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Orosco</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Panula</surname>
<given-names>P. J.</given-names>
</name>
</person-group>
<article-title>Oxidative Stress and Regulation of Pink1 in Zebrafish (Danio rerio)</article-title>
<source/>
<italic toggle="yes">PLoS ONE</italic>
<year>2013</year>
<volume>8</volume>
<issue>11</issue>
<fpage>p. e81851</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0081851</pub-id>
<pub-id pub-id-type="other">2-s2.0-84896707109</pub-id>
<pub-id pub-id-type="pmid">24324558</pub-id>
</element-citation>
</ref>
<ref id="B161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Motherwell</surname>
<given-names>M. S.</given-names>
</name>
</person-group>
<article-title>The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Gene</italic>
<year>2013</year>
<volume>532</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2013.07.085</pub-id>
<pub-id pub-id-type="other">2-s2.0-84885388816</pub-id>
<pub-id pub-id-type="pmid">23954870</pub-id>
</element-citation>
</ref>
<ref id="B162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilhelmus</surname>
<given-names>M. M. M.</given-names>
</name>
<name>
<surname>Nijland</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Drukarch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>van Horssen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders</article-title>
<source/>
<italic toggle="yes">Free Radical Biology &amp; Medicine</italic>
<year>2012</year>
<volume>53</volume>
<issue>4</issue>
<fpage>983</fpage>
<lpage>992</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.05.040</pub-id>
<pub-id pub-id-type="other">2-s2.0-84865036938</pub-id>
<pub-id pub-id-type="pmid">22687462</pub-id>
</element-citation>
</ref>
<ref id="B163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson's Disease</article-title>
<source/>
<italic toggle="yes">Cold Spring Harbor Perspectives in Medicine</italic>
<year>2012</year>
<volume>2</volume>
<issue>1</issue>
<fpage>a008888</fpage>
<lpage>a008888</lpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a008888</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872154697</pub-id>
<pub-id pub-id-type="pmid">22315721</pub-id>
</element-citation>
</ref>
<ref id="B164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>H.-X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of _TMEM230_ mutations in familial Parkinson's disease</article-title>
<source/>
<italic toggle="yes">Nature Genetics</italic>
<year>2016</year>
<volume>48</volume>
<issue>7</issue>
<fpage>733</fpage>
<lpage>739</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3589</pub-id>
<pub-id pub-id-type="other">2-s2.0-84976285813</pub-id>
<pub-id pub-id-type="pmid">27270108</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Parkinson's disease mechanism of action in the central nervous system and the pharmacokinetic effects of several agents that induce Parkinson-like symptoms. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) crosses the blood-brain barrier to be metabolized in 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B in the astrocytes. Afterwards, the transportation system of the synaptic cleft assists the intraneuronal MPP+ transfer and transports it further into the mitochondria where it impairs the mitochondrial respiration chain leading to reactive oxygen species production and dopaminergic neuron loss [<xref ref-type="bibr" rid="B21">21</xref>]. Similar to MPTP, paraquat could increase reactive oxygen species production, but in contrast to MPTP, it could lead to Lewy body (LB) formation [<xref ref-type="bibr" rid="B22">22</xref>]. 6-Hydroxidopamine could also enter the dopaminergic neurons and lead to reactive oxygen species production in the absence of the Lewy body inclusions [<xref ref-type="bibr" rid="B23">23</xref>]. Following diffusion to intraneuronal space, rotenone inhibits mitochondrial complex I and promotes the formation of Lewy body inclusions [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. Abbreviations: 6-OHDA—6-hydroxydopamine; ADP—adenosine diphosphate; ANT—adenine nucleotide translocase; ATP—adenosine triphosphate; BBB—blood-brain barrier; DA—dopamine; LB—Lewy bodies; L-DOPA—levodopa; MAO-B—monoamine oxidase B; MPP+—1-methyl-4-phenylpyridinium; MPTP—1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; OXPHOS—oxidative phosphorylation; ROS—reactive oxygen species; TH—tyrosine; VDAC—voltage-dependent anion channel.</p>
</caption>
<graphic xlink:href="OMCL2020-1370837.001"></graphic>
</fig>
<fig id="fig2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>The procedure used for the selection of scientific articles.</p>
</caption>
<graphic xlink:href="OMCL2020-1370837.002"></graphic>
</fig>
<fig id="fig3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Parkinson's disease molecular mechanisms and effects in the zebrafish central nervous system induced by several Parkinson's disease agents and treatment alternatives. Administration of these chemicals (MPTP, rotenone, paraquat, and 6-OHDA) through various ways can lead to a reduction in locomotor parameter activity, a decrease of dopamine neuron number, an increase of oxidative stress, and the inhibition of mitochondrial complex I promoting the formation of Lewy body inclusions [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B79">79</xref>]. Vitamin E, rasagiline, minocycline, and Sinemet can reverse the action of the Parkinson's disease agents mentioned above in zebrafish [<xref ref-type="bibr" rid="B80">80</xref>–<xref ref-type="bibr" rid="B82">82</xref>]. Abbreviations: ↑—increase; ↓—decrease; 6-OHDA—6-hydroxydopamine; A—dissolved in the water; ADP—adenosine diphosphate; ANT—adenine nucleotide translocase; ATP—adenosine triphosphate; B—intracerebroventricularly injection; BBB—blood-brain barrier; C—intraperitoneal injection; DA—dopamine; DpN—dopaminergic neuron; LB—Lewy bodies; L-DOPA—levodopa; LP—locomotor parameters; MPTP—1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MAO-B—monoamine oxidase B; MRC—mitochondrial respiratory chain; OS—oxidative stress; ROS—reactive oxygen species; TH—tyrosine.</p>
</caption>
<graphic xlink:href="OMCL2020-1370837.003"></graphic>
</fig>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Parkinson's disease animal models based on neuromodulation agents.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">PD-inducing agent</th>
<th align="center" colspan="1" rowspan="1">Model organism</th>
<th align="center" colspan="1" rowspan="1">Treatment</th>
<th align="center" colspan="1" rowspan="1">Route of administration</th>
<th align="center" colspan="1" rowspan="1">Effects</th>
<th align="center" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="7">MPTP</td>
<td align="center" colspan="1" rowspan="3">Zebrafish</td>
<td align="center" colspan="1" rowspan="1">5 <italic>μ</italic>g/ml and 10 <italic>μ</italic>g/ml, 3 days</td>
<td align="center" colspan="1" rowspan="1">Dissolved in the water</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>↓Pretectal area size<break></break>↓DA levels</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B55">55</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Single 20 mg/kg dose</td>
<td align="center" colspan="1" rowspan="1">Abdominal injection</td>
<td align="center" colspan="1" rowspan="1">↓DA and noradrenaline levels<break></break>↓Locomotor activity</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B40">40</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">1 × 50 <italic>μ</italic>g and 2 × 50 <italic>μ</italic>g/24 h</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>Evidence of freezing bouts</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B56">56</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3">Rat</td>
<td align="center" colspan="1" rowspan="1">Single 20 <italic>μ</italic>l/kg dose</td>
<td align="center" colspan="1" rowspan="1">Intrasubstantia nigra injection</td>
<td align="center" colspan="1" rowspan="1">↑MDA<break></break>↓SOD</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B57">57</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Single 100 <italic>μ</italic>g/1 <italic>μ</italic>l dose</td>
<td align="center" colspan="1" rowspan="1">Bilateral infusion</td>
<td align="center" colspan="1" rowspan="1">↑LPO<break></break>↓GSH<break></break>↑SOD levels in the striatum</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B58">58</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">1 <italic>μ</italic>mol/2 ml, in the 1st, 7th, and 14th day of the experiment</td>
<td align="center" colspan="1" rowspan="1">Intrasubstantia nigra injection</td>
<td align="center" colspan="1" rowspan="1">↑MDA<break></break>↓GSSH<break></break>↓CAT</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B59">59</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Mice</td>
<td align="center" colspan="1" rowspan="1">30 <italic>μ</italic>g/kg, twice at 16 h intervals</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓GSH<break></break>↓SOD in substantia nigra</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B60">60</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">6-OHDA</td>
<td align="center" colspan="1" rowspan="2">Zebrafish</td>
<td align="center" colspan="1" rowspan="1">Single dose: 25 mg/kg</td>
<td align="center" colspan="1" rowspan="1">Abdominal injection</td>
<td align="center" colspan="1" rowspan="1">↓Velocity rate and locomotor activity<break></break>↓DA neurons</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B48">48</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Single dose: 25 mg/kg</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓DA and noradrenaline levels<break></break>↓Locomotor activity</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B40">40</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2">Rats</td>
<td align="center" colspan="1" rowspan="1">10 <italic>μ</italic>g/2 <italic>μ</italic>l</td>
<td align="center" colspan="1" rowspan="1">Unilateral intrastriatal injection</td>
<td align="center" colspan="1" rowspan="1">↓GSH<break></break>↓CAT<break></break>↓SOD</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B19">19</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">8 mg/2 ml</td>
<td align="center" colspan="1" rowspan="1">Intrastriatal injection</td>
<td align="center" colspan="1" rowspan="1">↑MDA levels<break></break>↓GSH and SOD levels in striatum</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B20">20</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="11">Rotenone</td>
<td align="center" colspan="1" rowspan="2">Zebrafish</td>
<td align="center" colspan="1" rowspan="1">1-12 mg/kg, 7 to 36 consecutive days</td>
<td align="center" colspan="1" rowspan="1">Intravenous injection</td>
<td align="center" colspan="1" rowspan="1">↓DA neurons<break></break>↑<italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B15">15</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">5 <italic>μ</italic>g/l, 28 consecutive days</td>
<td align="center" colspan="1" rowspan="1">Dissolved in water</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>↓DA neurons<break></break>↑<italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B16">16</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="9">Rats</td>
<td align="center" colspan="1" rowspan="1">1.5 mg/kg and 2.5 mg/kg, 2 months</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓DA neurons in posterior striatum and prefrontal cortex<break></break>↑Catalepsy</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B17">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2.2-2.5 mg/kg, 28 consecutive days</td>
<td align="center" colspan="1" rowspan="1">Intravenous injection</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>↑<italic>α</italic>-Synuclein aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B61">61</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2.0-3.0 mg/kg, 28-56 days</td>
<td align="center" colspan="1" rowspan="1">Subcutaneous injection</td>
<td align="center" colspan="1" rowspan="1">↓DA neurons<break></break><italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B62">62</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Single 2.5 mg/kg dose</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓Body weight<break></break>↓DA neurons in striatum</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B63">63</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2-12 <italic>μ</italic>g/<italic>μ</italic>l, 28-90 days</td>
<td align="center" colspan="1" rowspan="1">Stereotaxial infusion</td>
<td align="center" colspan="1" rowspan="1">↑<italic>α</italic>-Syn aggregates<break></break>↓ROS level</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B64">64</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">2.0 mg/kg, 28 days</td>
<td align="center" colspan="1" rowspan="1">Subcutaneous injection</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>↓DA neurons<break></break>↑<italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B65">65</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">5 <italic>μ</italic>g, 21 days</td>
<td align="center" colspan="1" rowspan="1">Stereotaxial infusion</td>
<td align="center" colspan="1" rowspan="1">↓DA neurons<break></break>↑<italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B66">66</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">0.25-0.50 <italic>μ</italic>g, 21 days</td>
<td align="center" colspan="1" rowspan="1">Stereotaxial infusion</td>
<td align="center" colspan="1" rowspan="1">↑<italic>α</italic>-Syn aggregates</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B67">67</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">3 mg/kg, 30 days</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↑MDA levels<break></break>↓GSH and SOD levels</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B68">68</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Paraquat</td>
<td align="center" colspan="1" rowspan="2">Zebrafish</td>
<td align="center" colspan="1" rowspan="1">10 mg/kg, twice a day for 3 days</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↓Locomotor activity<break></break>Spatial memory impairments</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B69">69</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">1, 10, and 100 <italic>μ</italic>M, 4 days</td>
<td align="center" colspan="1" rowspan="1">Dissolved in the water</td>
<td align="center" colspan="1" rowspan="1">↓Mitochondrial respiration</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B70">70</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2">Mice</td>
<td align="center" colspan="1" rowspan="1">0, 0.89, 2.67, and 8 mg/kg, 28 days</td>
<td align="center" colspan="1" rowspan="1">Oral administration</td>
<td align="center" colspan="1" rowspan="1">↑MDA in HIP<break></break>↑Mitochondrial injury</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B71">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Paraquat (10 mg/kg) + maneb (30 mg/kg), twice a week, 9 weeks</td>
<td align="center" colspan="1" rowspan="1">Intraperitoneal injection</td>
<td align="center" colspan="1" rowspan="1">↑MDA<break></break>↑NO<break></break>↓GST</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B72">72</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>↑: increase; ↓: decrease; CAT: catalase; DA: dopamine; GPx: glutathione peroxidase; GSH: glutathione; GSSH: oxidised glutathione; GST: glutathione S-transferase; LPO: lipid hydroperoxide; MDA: malondialdehyde; NO: nitric oxide; SOD: superoxide dismutase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>